FEATURE_phases list | FEATURE_enrollmentCount int64 | FEATURE_allocation string | FEATURE_interventionModel string | FEATURE_primaryPurpose class label | FEATURE_masking class label | FEATURE_healthyVolunteers bool | FEATURE_sex class label | FEATURE_oversightHasDmc bool | FEATURE_briefSummary string | FEATURE_detailedDescription string | FEATURE_conditions string | FEATURE_conditionsKeywords string | FEATURE_protocolPdfText string | FEATURE_numArms int64 | FEATURE_armDescriptions string | FEATURE_armGroupTypes list | FEATURE_numInterventions int64 | FEATURE_interventionTypes list | FEATURE_interventionDescriptions string | FEATURE_interventionNames string | FEATURE_numLocations int64 | FEATURE_locationDetails string | LABEL_ct_level_ade_population int64 | LABEL_sum_dosing_errors int64 | LABEL_dosing_error_rate float32 | LABEL_wilson_label int64 | METADATA_nctId string | METADATA_overallStatus class label | METADATA_completionDate date32 | METADATA_startDate date32 | METADATA_leadSponsorName string | METADATA_leadSponsorClass class label | METADATA_hasProtocol bool | METADATA_hasSap bool | METADATA_hasIcf bool | METADATA_protocolPdfLinks string | METADATA_count_Accidental drug intake by child int64 | METADATA_count_Accidental overdose int64 | METADATA_count_Accidental overdose (therapeutic agent) int64 | METADATA_count_Accidental underdose int64 | METADATA_count_Deliberate overdose int64 | METADATA_count_Dose calculation error int64 | METADATA_count_Drug administration error int64 | METADATA_count_Drug overdose int64 | METADATA_count_Drug overdose accidental int64 | METADATA_count_Extra dose administered int64 | METADATA_count_Incorrect dosage administered int64 | METADATA_count_Incorrect dose administered int64 | METADATA_count_Incorrect drug administration duration int64 | METADATA_count_Incorrect drug administration rate int64 | METADATA_count_Incorrect product administration duration int64 | METADATA_count_Intentional overdose int64 | METADATA_count_Medication error int64 | METADATA_count_Medication monitoring error int64 | METADATA_count_Multiple drug overdose int64 | METADATA_count_Multiple drug overdose accidental int64 | METADATA_count_Multiple drug overdose intentional int64 | METADATA_count_Multiple use of single-use product int64 | METADATA_count_Non-accidental overdose int64 | METADATA_count_Overdose int64 | METADATA_count_Overdose NOS int64 | METADATA_count_Overmedication int64 | METADATA_count_Prescribed overdose int64 | METADATA_count_Treatment noncompliance int64 | METADATA_count_Underdose int64 | METADATA_count_Unintentional medical device removal int64 | METADATA_count_Unintentional medical device removal by patient int64 | METADATA_wilson_lower_bound float32 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
[
3
] | 38 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | This study will evaluate whether AG-013736 when combined with cisplatin and gemcitabine shows activity and is safe in patients with squamous type of non-small cell lung cancer | null | Carcinoma, Non-Small-Cell Lung (NSCLC) | AG-013736 axitinib cisplatin gemcitabine NSCLC squamous cell lung cancer | null | 1 | arm 1: None | [
0
] | 3 | [
0,
0,
0
] | intervention 1: AG-013736 5 mg tablets orally, twice daily, until disease progression intervention 2: 200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles intervention 3: 1mg/ml solution or as lyophilized powder, to be administere... | intervention 1: AG-013736 intervention 2: gemcitabine intervention 3: cisplatin | 10 | Torun | N/A | Poland | 18.59814 | 53.01375
Wodzislaw Sl. | N/A | Poland | N/A | N/A
Cluj-Napoca | Cluj | Romania | 23.6 | 46.76667
Bucharest | N/A | Romania | 26.10626 | 44.43225
Oradea | N/A | Romania | 21.91833 | 47.0458
Parktown | N/A | South Africa | 28.02671 | -26.18205
Dnipropetrovsk | N/A | Ukraine | 35.04066 | ... | 38 | 0 | 0 | 0 | NCT00735904 | 1COMPLETED | 2011-11-01 | 2008-12-01 | Pfizer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3,
4
] | 91 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | Visual outcomes using monthly ranibizumab therapy are well established in clinical trials, but the best way to assess when and how to treat patients with PRN therapy has not been proven. Information is lacking on Multi-focal ERG and microperimetry outcomes with ranibizumab therapy. Additionally, VA and OCT outcomes don... | null | Neovascular Age Related Macular Degeneration | ARMD AMD exudative AMD | null | 2 | arm 1: Ranibizumab injections every month for 12 months. arm 2: Ranibizumab injections monthly for 4 months then as needed thereafter. | [
1,
1
] | 2 | [
1,
0
] | intervention 1: OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.
Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.
Multifocal E... | intervention 1: OCT, Multifocal ERG, Microperimetry intervention 2: Ranibizumab Ophthalmic | 1 | Torrance | California | United States | -118.34063 | 33.83585 | 77 | 0 | 0 | 0 | NCT00764738 | 1COMPLETED | 2011-11-01 | 2008-10-01 | Retina Macula Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 |
[
3
] | 719 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | The objective was to investigate the antiviral effect, safety, and pharmacokinetics of BI 201335 (Faldaprevir), given as a soft gelatine capsule, in patients with hepatitis C virus (HCV) genotype 1 infection. Combination therapy of BI 201335 (Faldaprevir) with pegylated interferon α-2a (PegIFN) and ribavirin (RBV), wit... | null | Hepatitis C, Chronic | null | 7 | arm 1: 240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients arm 2: 240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 we... | [
0,
0,
2,
0,
0,
0,
0
] | 14 | [
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] | intervention 1: 240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks intervention 2: PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks intervention 3: 120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks intervention 4: PegIFN (180 µg/wk) and RBV (1000/1200mg/d),4... | intervention 1: BI 201335 NA 240 mg QD / LI intervention 2: PegIFN/RBV intervention 3: BI 201335 NA 120mg QD / LI intervention 4: PegIFN/RBV intervention 5: BI 201335 NA 240 mg QD intervention 6: PegIFN/RBV intervention 7: BI 201335 NA 240 mg QD intervention 8: PegIFN/RBV intervention 9: BI 201335 NA 240 mg BID interve... | 100 | San Francisco | California | United States | -122.41942 | 37.77493
San Francisco | California | United States | -122.41942 | 37.77493
Chicago | Illinois | United States | -87.65005 | 41.85003
Lutherville | Maryland | United States | -76.62608 | 39.42122
New York | New York | United States | -74.00597 | 40.71427
New Yor... | 712 | 0 | 0 | 0 | NCT00774397 | 1COMPLETED | 2011-11-01 | 2008-10-01 | Boehringer Ingelheim | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 15 | RANDOMIZED | CROSSOVER | 0TREATMENT | 3TRIPLE | true | 0ALL | false | To determine whether the combination of ezetimibe and simvastatin improves biomarkers of atherothrombosis compared to simvastatin alone in patients with the metabolic syndrome. | 1. To assess the ex vivo effects of ezetimibe/simvastatin (E/S) (Vytorin 10/40mg) and simvastatin (S) (Zocor 40mg) on platelet and inflammation biomarkers in patients with documented metabolic syndrome.
2. To compare platelet-related effects including PAR-1 receptor inhibition of E/S with those of the established anti-... | Metabolic Syndrome | triglycerides hypertension low hdl obesity | null | 2 | arm 1: Simvastatin 40 mg daily arm 2: Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied. | [
1,
1
] | 2 | [
0,
0
] | intervention 1: Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied. intervention 2: Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied. | intervention 1: simvastatin intervention 2: ezetimibe/simvastatin | 3 | Baltimore | Maryland | United States | -76.61219 | 39.29038
Baltimore | Maryland | United States | -76.61219 | 39.29038
Baltimore | Maryland | United States | -76.61219 | 39.29038 | 30 | 0 | 0 | 0 | NCT00819403 | 1COMPLETED | 2011-11-01 | 2009-01-01 | University of Maryland, Baltimore | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 15 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The primary objective is to evaluate the Patent Ductus Arteriosus (PDA) closure rate of early vs. late use of Ibuprofen (Ibu). The investigators believe that early use of Ibu will have a higher PDA closure rate than later use of Ibu. Early use is defined as medication given before the infant reaches 96 hrs old. Late us... | Infants with birth weight at \<1200gm and/or \<28 weeks gestation who have been diagnosed with a Patent Ductus Arteriosus (PDA) qualify for the study if there are no contraindications to treatment. Infants are randomized into treatment arms of \<96 hrs old and \>96 hrs old. Ibuprofen is given in the dosage of 10 mg/kg ... | Patent Ductus Arteriosus Prematurity | premature infants PDA ibuprofen | null | 2 | arm 1: Infants randomized to this group will receive their initial dose of ibuprofen prior to reaching 96 hrs old arm 2: Infants randomized to this group will receive their initial dose of ibuprofen after infant has reached 96 hrs old but before the infant reaches 10 days old. | [
1,
1
] | 2 | [
0,
0
] | intervention 1: Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose intervention 2: Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg | intervention 1: Ibuprofen intervention 2: Ibuprofen | 1 | Salt Lake City | Utah | United States | -111.89105 | 40.76078 | 15 | 0 | 0 | 0 | NCT00833365 | 6TERMINATED | 2011-11-01 | 2009-01-01 | University of Utah | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 295 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | The purpose of this study is to assess the long-term safety and tolerability and to explore the long-term efficacy of zonisamide as monotherapy treatment in subjects with newly diagnosed partial seizures. | null | Epilepsy | Epilepsy Monotherapy | null | 2 | arm 1: None arm 2: None | [
1,
1
] | 2 | [
0,
0
] | intervention 1: Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respect... | intervention 1: Zonisamide intervention 2: Carbamazepine | 133 | Camperdown | New South Wales | Australia | 151.17642 | -33.88965
Bedford Park | South Australia | Australia | 138.56815 | -35.02204
Clayton | Victoria | Australia | 145.11667 | -37.91667
Fitzroy | Victoria | Australia | 144.97833 | -37.79839
Heidelberg West | Victoria | Australia | 145.04034 | -37.73922
Parkville | Vic... | 876 | 0 | 0 | 0 | NCT00848549 | 1COMPLETED | 2011-11-01 | 2008-10-01 | Eisai Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 13 | NON_RANDOMIZED | SEQUENTIAL | 0TREATMENT | 0NONE | false | 0ALL | true | RATIONALE: Human T-cell lymphotropic virus type 1 (HTLV-1) can cause cancer. Zidovudine is an antiviral drug that acts against the human T-cell lymphotropic virus type 1. Giving zidovudine, interferon alfa-2b, and PEG-interferon alfa-2b together may stimulate the immune system and slow down or keep the cancer cell from... | OUTLINE: This is a multicenter study.
* Induction therapy: Patients receive zidovudine IV twice daily on days 1-14, and recombinant interferon alfa-2b IV twice daily on days 3-14. Patients achieving clinical complete response (CR) proceed to part 1 maintenance therapy; patients achieving partial response (PR) receive ... | Lymphoma Precancerous/Nonmalignant Condition | recurrent adult T-cell leukemia/lymphoma stage I adult T-cell leukemia/lymphoma stage II adult T-cell leukemia/lymphoma stage III adult T-cell leukemia/lymphoma stage IV adult T-cell leukemia/lymphoma HTLV-1 infection | null | 4 | arm 1: For one cycle, up to Day 21. All participants are enrolled to induction therapy phase, then move to the maintenance therapy phase if they achieve complete response (PR) or partial response (PR). Participants who achieve a clinical CR at Day 14 response assessment will go on to Part 1 maintenance therapy. Patient... | [
0,
0,
0,
0
] | 4 | [
2,
2,
0,
0
] | intervention 1: Administered subcutaneously. intervention 2: Administered intravenously. intervention 3: Administered orally. intervention 4: Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B). | intervention 1: PEG-interferon alfa-2b intervention 2: Interferon alfa-2b intervention 3: Valproic Acid intervention 4: Zidovudine | 1 | Miami | Florida | United States | -80.19366 | 25.77427 | 25 | 0 | 0 | 0 | NCT00854581 | 6TERMINATED | 2011-11-01 | 2007-11-01 | University of Miami | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 31 | NON_RANDOMIZED | SINGLE_GROUP | 2DIAGNOSTIC | 1SINGLE | false | 0ALL | false | The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls. | null | Parkinson's Disease | amyloid burden Parkinson's disease florbetapir PET amyloid PET imaging | null | 3 | arm 1: Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores of ≥9, indicating normal cognitive performance. arm 2: Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores between 6 and 8, inclusive, indicating mild cognitive deficits. arm 3: Subject... | [
0,
0,
0
] | 1 | [
0
] | intervention 1: 10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection | intervention 1: florbetapir F 18 | 1 | Philadelphia | Pennsylvania | United States | -75.16362 | 39.95238 | 31 | 0 | 0 | 0 | NCT00857532 | 1COMPLETED | 2011-11-01 | 2009-01-01 | Avid Radiopharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 26 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | Everolimus is an oral mTOR inhibitor with demonstrated preliminary efficacy and safety in diffuse large B-cell lymphoma (DLBCL) in both preclinical and clinical studies. The purpose of this research study is to determine whether Everolimus plus rituximab is safe and effective in participants with relapsed or refractory... | Participants will receive oral Everolimus and intravenous rituximab for DLBCL that has relapsed or been refractory to prior therapy.
* Each treatment cycle lasts 28 days (4 weeks). Everolimus will be taken orally, once daily in the morning.
* Rituximab will be administered by an intravenous (IV) infusion on Days 1, 8,... | Diffuse Large B-cell Lymphoma | rituximab everolimus DLBCL mTOR | null | 0 | null | null | 2 | [
0,
0
] | intervention 1: Taken orally once daily in the morning intervention 2: Given intravenously on Days 1, 8, 15, and 22 of Cycle 1 then on Day 1 of cycles 2-6 | intervention 1: Everolimus intervention 2: rituximab | 2 | Boston | Massachusetts | United States | -71.05977 | 42.35843
Boston | Massachusetts | United States | -71.05977 | 42.35843 | 24 | 0 | 0 | 0 | NCT00869999 | 1COMPLETED | 2011-11-01 | 2009-05-01 | Massachusetts General Hospital | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2,
3
] | 4 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 2MALE | true | RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blo... | PRIMARY OBJECTIVES:
I. To evaluate the response by prostate specific antigen (PSA) of docetaxel/prednisone plus sunitinib (sunitinib malate) in chemotherapy-naive, hormone refractory prostate cancer subjects with biochemical relapse.
SECONDARY OBJECTIVES:
I. To determine the objective response rate (ORR) and duratio... | Prostate Cancer Adenocarcinoma of the Prostate Recurrent Prostate Cancer Stage I Prostate Cancer Stage III Prostate Cancer Stage IV Prostate Cancer | null | 1 | arm 1: Patients receive docetaxel IV over 60 minutes on day 1, prednisone PO BID on days 1-21, and sunitinib malate PO QD on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat ... | [
0
] | 3 | [
0,
0,
0
] | intervention 1: Given PO intervention 2: Given IV intervention 3: Given PO | intervention 1: sunitinib malate intervention 2: docetaxel intervention 3: prednisone | 1 | Orange | California | United States | -117.85311 | 33.78779 | 4 | 0 | 0 | 0 | NCT00879619 | 6TERMINATED | 2011-11-01 | 2009-07-01 | John P. Fruehauf | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 214 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) | NAP | Partial Epilepsy | null | 1 | arm 1: Open Label Study | [
5
] | 1 | [
0
] | intervention 1: Open Label Study | intervention 1: Oxcarbazepine XR | 58 | Huntsville | Alabama | United States | -86.58594 | 34.7304
Northport | Alabama | United States | -87.57723 | 33.22901
Phoenix | Arizona | United States | -112.07404 | 33.44838
Tucson | Arizona | United States | -110.92648 | 32.22174
Little Rock | Arkansas | United States | -92.28959 | 34.74648
Riverside | California | ... | 214 | 0 | 0 | 0 | NCT00908349 | 1COMPLETED | 2011-11-01 | 2009-06-01 | Supernus Pharmaceuticals, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 2 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size. | Gonadotroph adenomas are the most common pituitary macroadenomas. Currently no medical treatment as been found that decreases the size of these adenomas, so surgery is the only treatment. The reason to think that pasireotide might affect gonadotroph adenomas is that pasireotide binds avidly to somatostatin subtype 5 re... | Gonadotroph Adenomas | pituitary tumor endocrine | null | 1 | arm 1: 80 mg IM once monthly | [
0
] | 1 | [
0
] | intervention 1: pasireotide LAR 80 mg IM once a month | intervention 1: pasireotide LAR | 1 | Philadelphia | Pennsylvania | United States | -75.16362 | 39.95238 | 2 | 0 | 0 | 0 | NCT00929669 | 6TERMINATED | 2011-11-01 | 2009-06-01 | University of Pennsylvania | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 12 | NA | SINGLE_GROUP | 7BASIC_SCIENCE | 0NONE | true | 0ALL | false | DESCRIPTION: (Verbatim from the Applicant's Abstract) Abnormalities of eye movement control and spatial cognition are well-established deficits in schizophrenia. However, the regional disturbances in brain function causing these deficits are not yet known. This application proposes a series of integrated behavioral stu... | We will be assessing clinical symptoms and cognition before and after treatment. | Schizophrenia | schizophrenia antipsychotic risperidone | null | 1 | arm 1: Antipsychotic | [
0
] | 1 | [
0
] | intervention 1: Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks. | intervention 1: Antipsychotic | 1 | Chicago | Illinois | United States | -87.65005 | 41.85003 | 12 | 0 | 0 | 0 | NCT00931996 | 6TERMINATED | 2011-11-01 | 2009-06-01 | University of Illinois at Chicago | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 60 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | This was a long-term safety study HPN-100 in urea cycle disorder (UCD) subjects. Subjects were assessed regularly for safety and control of their venous ammonia. Hyperammonemic events were characterized with respect to contributing factors, such as intercurrent illness, diet, and noncompliance with medication. | This was a one year long-term safety study of HPN-100 in UCD subjects. Subjects were assessed regularly for safety and control of their venous ammonia. Hyperammonemic events were characterized with respect to contributing factors, such as intercurrent illness, diet, and noncompliance with medication.
Forty subjects wi... | Urea Cycle Disorders | Urea Cycle Disorder UCD hyperammonemia Buphenyl Sodium Phenylbutyrate | null | 1 | arm 1: Patients who were treated with HPN-100 | [
0
] | 1 | [
0
] | intervention 1: HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (\~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do. | intervention 1: HPN-100 | 22 | Long Beach | California | United States | -118.18923 | 33.76696
Los Angeles | California | United States | -118.24368 | 34.05223
Stanford | California | United States | -122.16608 | 37.42411
Aurora | Colorado | United States | -104.83192 | 39.72943
New Haven | Connecticut | United States | -72.92816 | 41.30815
Washingt... | 60 | 0 | 0 | 0 | NCT00947297 | 1COMPLETED | 2011-11-01 | 2009-11-01 | Amgen | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 9 | RANDOMIZED | PARALLEL | 4SUPPORTIVE_CARE | 0NONE | false | 0ALL | true | RATIONALE: Cyproheptadine hydrochloride may help improve appetite and lessen weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine hydrochloride is more effective with or without nutritional supplementation in improving weight and quality of life of young patients with weight loss... | OBJECTIVES:
Primary
* To compare the efficacy of an appetite stimulant, cyproheptadine hydrochloride, with vs without a nutritional supplement, PediaSure or Ensure, in improving weight and extending the duration of response in pediatric patients with cancer- or cancer treatment-related weight loss.
Secondary
* To c... | Leukemia Lymphoma Malnutrition Myelodysplastic Syndromes Unspecified Childhood Solid Tumor, Protocol Specific Weight Changes | malnutrition weight changes childhood acute lymphoblastic leukemia in remission recurrent childhood acute lymphoblastic leukemia untreated childhood acute lymphoblastic leukemia childhood acute myeloid leukemia in remission recurrent childhood acute myeloid leukemia untreated childhood acute myeloid leukemia other myel... | null | 2 | arm 1: Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity. arm 2: Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (\> 10 years of age) twice daily for up to 24 weeks i... | [
0,
0
] | 3 | [
7,
7,
0
] | intervention 1: Given orally intervention 2: Given orally intervention 3: Given orally | intervention 1: Ensure intervention 2: PediaSure intervention 3: cyproheptadine hydrochloride | 0 | null | 9 | 0 | 0 | 0 | NCT00949117 | 6TERMINATED | 2011-11-01 | 2009-09-01 | University of South Florida | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 35 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | Ropivacaine 0.5% and 0.5% in levobupivacaïne are used in regional anesthesia for major surgery of the foot. The literature does not highlight a significant difference in terms of onset of action between these two molecules to block the sciatic nerve \[4\]. Our hypothesis is that this lack of difference is due to the us... | null | Nerve Block | null | 2 | arm 1: None arm 2: None | [
1,
1
] | 2 | [
0,
0
] | intervention 1: 20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 % intervention 2: 20mL de ropivacaïne 0,5 % | intervention 1: levobupivacaïne 0,5 % intervention 2: ropivacaïne 0,5 % | 1 | Nantes | N/A | France | -1.55336 | 47.21725 | 35 | 0 | 0 | 0 | NCT00956709 | 6TERMINATED | 2011-11-01 | 2008-12-01 | Nantes University Hospital | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
0
] | 67 | NA | SINGLE_GROUP | null | 0NONE | false | 0ALL | null | RATIONALE: A study that evaluates participants' beliefs about smokeless tobacco products and nicotine replacement therapy may be useful in helping smokers stop smoking.
PURPOSE: This clinical trial is studying the acceptability of less harmful alternatives to cigarettes. | OBJECTIVES:
Primary
* To assess the impact of factual information (a fact sheet) about the relative harms of smokeless (SL)/nicotine replacement (NR) products on participants' beliefs about relative harmfulness.
* To assess the impact of trying samples of NR and/or SL products on intentions to use such products as al... | Bladder Cancer Cervical Cancer Esophageal Cancer Gastric Cancer Head and Neck Cancer Kidney Cancer Leukemia Liver Cancer Lung Cancer Pancreatic Cancer Tobacco Use Disorder | tobacco use disorder bladder cancer cervical cancer esophageal cancer gastric cancer renal cell carcinoma adult primary liver cancer non-small cell lung cancer small cell lung cancer pancreatic cancer hypopharyngeal cancer laryngeal cancer lip and oral cavity cancer nasopharyngeal cancer oropharyngeal cancer paranasal ... | null | 1 | arm 1: Single-armed study | [
5
] | 5 | [
5,
0,
10,
10,
10
] | intervention 1: 10-15 minute web-based survey on a computer intervention 2: One week supply intervention 3: None intervention 4: None intervention 5: Given out week 2, 3 and 4. | intervention 1: telephone-based intervention intervention 2: nicotine replacement therapy intervention 3: informational intervention intervention 4: internet-based intervention intervention 5: questionnaire administration | 1 | Buffalo | New York | United States | -78.87837 | 42.88645 | 59 | 0 | 0 | 0 | NCT00957424 | 1COMPLETED | 2011-11-01 | 2009-06-01 | Roswell Park Cancer Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 25 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to conduct a clinical trial of two formulations of budesonide (nebulized/swallowed versus viscous/swallowed) in patients with EoE to determine if medication contact time and distribution in the esophagus relates to treatment response. The investigators will also determine if there is system... | null | Eosinophilic Esophagitis | eosinophilic esophagitis | null | 2 | arm 1: None arm 2: None | [
0,
1
] | 2 | [
0,
0
] | intervention 1: medication will be nebulized and then swallowed intervention 2: viscous suspension of budesonide will be swallowed | intervention 1: inhaled/swallowed budesonide intervention 2: viscous/swallowed budesonide | 1 | Chapel Hill | North Carolina | United States | -79.05584 | 35.9132 | 22 | 0 | 0 | 0 | NCT00961233 | 1COMPLETED | 2011-11-01 | 2009-10-01 | University of North Carolina, Chapel Hill | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 169 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 1FEMALE | false | The purpose of this study is to assess the safety and effectiveness of S-equol in menopausal patients with hot flushes and night sweats. | The study is a randomized, double blind, multicenter, placebo controlled, parallel group, proof of concept study comparing the efficacy, safety, and acceptability of 3 doses of S-equol to placebo in menopausal patients with vasomotor symptoms. The study objective is an evaluation of the dose response of 3 dose levels o... | Menopause | null | 4 | arm 1: Placebo arm 2: S-equol 20 mg total daily dose arm 3: S-equol 100 mg total daily dose arm 4: S-equol 300 mg total daily dose | [
2,
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: None intervention 2: Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:
* S-equol 10 mg BID (20 mg total daily dose)
* S-equol 50 mg BID (100 mg total daily dose)
* S-equol 150 mg BID (300 mg total daily dose) | intervention 1: Placebo intervention 2: S-equol | 9 | Louisville | Kentucky | United States | -85.75941 | 38.25424
Cincinnati | Ohio | United States | -84.51439 | 39.12711
Cleveland | Ohio | United States | -81.69541 | 41.4995
Greenville | South Carolina | United States | -82.39401 | 34.85262
West Jordon | Utah | United States | N/A | N/A
Ashfield | New South Wales | Aust... | 169 | 0 | 0 | 0 | NCT00962585 | 1COMPLETED | 2011-11-01 | 2010-06-01 | Ausio Pharmaceuticals, LLC | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 344 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | The purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an inhibitor of gastric acid secretion of the protein pump inhibitor (PPI) class, compared with placebo in the treatment of gastrointestinal esophageal reflux disease (GERD) in infants 1 to 11 months of age. | Rabeprazole sodium belongs to the class of drugs known as proton pump inhibitors, which suppress gastric acid secretion. The drug is approved in the United States for the treatment of adults with GERD and other acid-related gastrointestinal disorders, and has been studied in adolescents (older than 12 years of age) wit... | Gastroesophageal Reflux | Gastroesophageal Reflux Gastroesophageal Reflux Disease GERD Proton Pump Inhibitor PPI Regurgitation Infants AcipHex, PARIET ALFENCE | null | 3 | arm 1: None arm 2: None arm 3: None | [
0,
0,
2
] | 3 | [
0,
0,
0
] | intervention 1: Rabeprazole Sodium 5 mg capsules once daily in the morning. intervention 2: Rabeprazole Sodium 10 mg capsules once daily in the morning. intervention 3: Matching placebo capsules once daily in the morning. | intervention 1: Rabeprazole sodium 5 mg intervention 2: Rabeprazole sodium 10 mg intervention 3: Placebo | 81 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Columbiana | Alabama | United States | -86.60721 | 33.17817
Dothan | Alabama | United States | -85.39049 | 31.22323
Huntsville | Alabama | United States | -86.58594 | 34.7304
Mobile | Alabama | United States | -88.04305 | 30.69436
Phoenix | Arizona | United St... | 611 | 0 | 0 | 0 | NCT00992589 | 1COMPLETED | 2011-11-01 | 2009-11-01 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 107 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The objective is to identify the optimal dose of SABER-Bupivacaine for postoperative pain control in patients undergoing elective arthroscopic shoulder surgery on the basis of pharmacokinetics, efficacy and safety evaluations. The study duration consists of a screening period up to 14 days and a treatment period 14 day... | null | Postoperative Pain | Post operative pain Local anaesthesia Postoperative pain after arthroscopic shoulder surgery | null | 6 | arm 1: double-blind arm 2: double-blind arm 3: double-blind arm 4: double-blind arm 5: double-blind arm 6: double-blind | [
0,
2,
1,
0,
2,
1
] | 6 | [
0,
0,
0,
0,
0,
0
] | intervention 1: 5.0 ml intervention 2: 5.0 ml intervention 3: 20.0 ml intervention 4: 7.5 ml intervention 5: 7.5 ml intervention 6: 20.0 ml | intervention 1: SABER-Bupivacaine Treatment 1a intervention 2: Placebo SABER-Bupivacaine Treatment 1b intervention 3: Bupivacaine HCl Treatment 1c intervention 4: SABER-Bupivacaine Treatment 2a intervention 5: Placebo SABER-Bupivacaine Treatment 2b intervention 6: Bupivacaine HCl Treatment 2c | 10 | Graz | N/A | Austria | 15.45 | 47.06667
Vienna | N/A | Austria | 16.37208 | 48.20849
Vienna | N/A | Austria | 16.37208 | 48.20849
Berlin | N/A | Germany | 13.41053 | 52.52437
Dresden | N/A | Germany | 13.73832 | 51.05089
Marburg | N/A | Germany | 8.77069 | 50.80904
Riga | N/A | Latvia | 24.10589 | 56.946
Valmiera | N/A... | 107 | 0 | 0 | 0 | NCT00993798 | 1COMPLETED | 2011-11-01 | 2009-04-01 | Durect | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 837 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to compare the safety and tolerability of azilsartan medoxomil plus chlorthalidone, once daily (QD), versus olmesartan medoxomil-hydrochlorothiazide in adults with essential hypertension. | High Blood Pressure (Hypertension) is the most common cause of preventable death in developed nations. Uncontrolled hypertension greatly increases the risk of heart disease, brain disease, and kidney failure. As the population ages, the incidence of hypertension will continue to increase if effective preventive measure... | Essential Hypertension | Hypertensive Blood Pressure, High Cardiovascular disease Vascular Disease Drug Therapy | null | 2 | arm 1: Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily for up to 52 weeks.
For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of azilsartan medoxomil 80 mg and chlorthalidone 25 mg. arm 2: Participants in the United States:
Ol... | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Combination tablet. intervention 2: Combination tablet. | intervention 1: Azilsartan medoxomil and chlorthalidone intervention 2: Olmesartan medoxomil and hydrochlorothiazide | 26 | Graz | Styria | Austria | 15.45 | 47.06667
Karlsruhe | Baden-Wurttemberg | Germany | 8.40444 | 49.00937
Hanover | Lower Saxony | Germany | 9.73322 | 52.37052
Kiel-Kronshagen | Schleswig-Holstein | Germany | N/A | N/A
Breda | North Brabant | Netherlands | 4.77596 | 51.58656
Eindhoven | North Brabant | Netherlands | 5.47... | 837 | 0 | 0 | 0 | NCT00996281 | 1COMPLETED | 2011-11-01 | 2009-10-01 | Takeda | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 22 | RANDOMIZED | CROSSOVER | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The purpose of this study is to determine if treatment with paricalcitol, an active form of vitamin D, has beneficial effects on metabolic abnormalities in people with stage 3-4 Chronic Kidney Disease (CKD). | Persons with chronic kidney disease (CKD) are at markedly increased risk of death, particularly from cardiovascular disease (CVD). A number of metabolic abnormalities may contribute to adverse health outcomes in CKD, including glucose intolerance, altered immune cell function, and oxidative stress. Each of these metabo... | Chronic Kidney Disease | Chronic kidney disease Vitamin D Paricalcitol Placebo Kidney Renal Oxidative Stress Immune cell function Glucose Glucose tolerance | null | 2 | arm 1: Participants will receive paricalcitol for 8 weeks, then an 8-week wash-out, then placebo for 8 weeks. arm 2: Participants will receive placebo for 8 weeks, then an 8-week wash-out, then paricalcitol for 8 weeks. | [
1,
1
] | 2 | [
0,
0
] | intervention 1: Two 1 mcg soft gels by mouth daily for 8 weeks intervention 2: Two soft gels by mouth daily for 8 weeks | intervention 1: Paricalcitol intervention 2: Placebo | 1 | Seattle | Washington | United States | -122.33207 | 47.60621 | 43 | 0 | 0 | 0 | NCT01003275 | 1COMPLETED | 2011-11-01 | 2009-10-01 | University of Washington | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 43 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | null | To explore the efficacy of BIBW 2992 defined by the objective response rate (Complete Response, Partial Response) as determined by Response Evaluation Criteria in Solid Tumours\[RECIST\] 1.1 in the patients with advanced (stage IIIB or IV) adenocarcinoma of the lung harbouring wild-type EGFR. | null | Carcinoma, Non-Small-Cell Lung | null | 1 | arm 1: patient to receive afatinib(BIBW 2992) po QD in an open-label manner | [
0
] | 1 | [
0
] | intervention 1: afatinib (BIBW 2992) po QD | intervention 1: afatinib (BIBW 2992) | 3 | Seoul | N/A | South Korea | 126.9784 | 37.566
Seoul | N/A | South Korea | 126.9784 | 37.566
Seoul | N/A | South Korea | 126.9784 | 37.566 | 42 | 0 | 0 | 0 | NCT01003899 | 1COMPLETED | 2011-11-01 | 2009-10-01 | Boehringer Ingelheim | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 8 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | If subjects are listed for kidney transplant and are considered sensitized, this means they have a high amount of antibodies in their blood that could react to a kidney transplant offered for them. Antibodies are protein substances made by the body that fight anything that the body considers as a threat to it, such as ... | Approximately one third of patients awaiting kidney transplant at our transplant center have significant levels of antibodies in their blood leading to a longer wait time for a kidney transplant and death. Antibodies in the blood may be due to prior transplants, pregnancy, or blood transfusions. These antibodies sensit... | Desensitization | belimumab Benlysta LymphoStat B BLyS specific inhibitors | null | 1 | arm 1: Belimumab will be administered intravenously at a dose of 10mg/kg on days 0, 14, 28 and every 28 days for up to 52 weeks to normalize alloantibody levels in sensitized patients awaiting kidney transplantation. Subjects who are not able to undergo transplantation before the end of the treatment period will have f... | [
0
] | 1 | [
0
] | intervention 1: Belimumab is a fully human monoclonal antibody that recognizes and inhibits BLyS ®. BLyS ® is a B-lymphocyte stimulator protein which plays a role in the development of B lymphocyte cells into plasma B cells, which then produce antibodies that can sensitize a potential transplant recipient. At the time ... | intervention 1: Belimumab | 1 | Philadelphia | Pennsylvania | United States | -75.16362 | 39.95238 | 8 | 0 | 0 | 0 | NCT01025193 | 6TERMINATED | 2011-11-01 | 2010-02-01 | University of Pennsylvania | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 7 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to determine the response rate by RECIST criteria of oral dichloroacetate in patients with recurrent and/or metastatic and pretreated breast and non-small cell lung cancer. | In the United States, approximately 180,000 new cases of breast cancer occur annually, and there are more than 40,000 deaths. More than 150,000 cases develop each year in Canada and the European community together, resulting in over 60,000 deaths from breast cancer. The vast majority of patients who die from breast can... | Metastatic Breast Cancer Lung Cancer | metastatic breast cancer lung cancer Previously treated metastatic breast cancer stage IIIb lung cancer stage IV lung cancer | null | 1 | arm 1: Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart. | [
0
] | 1 | [
0
] | intervention 1: Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart | intervention 1: Dichloroacetate (DCA) | 1 | Los Angeles | California | United States | -118.24368 | 34.05223 | 7 | 0 | 0 | 0 | NCT01029925 | 6TERMINATED | 2011-11-01 | 2009-12-01 | Jonsson Comprehensive Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 773 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | null | This is a Double-blind study wherein patients with Major Depressive Disorder (MDD) will receive either from 1 to 3 mg a day of study medication (OPC-34712)or placebo (an inactive substance) in addition to an FDA approved antidepressant in order to determine if the study medication is effective as an add on treatment of... | null | Major Depressive Disorder | OPC-34712 Major Depressive Disorder Adjunctive Treatment | null | 2 | arm 1: OPC-34712 Tablets, Oral, 1 - 3 mg OPC-34712 + ADT arm 2: Placebo + ADT | [
0,
2
] | 3 | [
0,
0,
0
] | intervention 1: Tablets, Oral, 1 - 3 mg OPC-34712 intervention 2: Placebo intervention 3: None | intervention 1: OPC-34712 intervention 2: Placebo intervention 3: ADT | 43 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Arcadia | California | United States | -118.03534 | 34.13973
Beverly Hills | California | United States | -118.40036 | 34.07362
Oceanside | California | United States | -117.37948 | 33.19587
San Diego | California | United States | -117.16472 | 32.71571
Santa ... | 372 | 0 | 0 | 0 | NCT01052077 | 1COMPLETED | 2011-11-01 | 2010-03-01 | Otsuka Pharmaceutical Development & Commercialization, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 48 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | This study tests two different approaches to the removal of dead tissue from the surface of a wound. | null | Diabetic Foot Ulcers Foot Wounds | Diabetic Foot Ulcers Diabetic Foot Wounds | null | 2 | arm 1: 2 mm Santyl applied once daily arm 2: Daily gauze and optional sharp debridement | [
1,
3
] | 2 | [
0,
3
] | intervention 1: 2 mm Santyl applied once daily. intervention 2: Daily gauze and optional sharp debridement | intervention 1: Santyl intervention 2: Control | 9 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Lincoln | Nebraska | United States | -96.66696 | 40.8
Altoona | Pennsylvania | United States | -78.39474 | 40.51868
Langhorne | Pennsylvania | United States | -74.92267 | 40.17455
Philadelphia | Pennsylvania | United States | -75.16362 | 39.95238
Arlington | Tex... | 48 | 0 | 0 | 0 | NCT01056198 | 1COMPLETED | 2011-11-01 | 2010-02-01 | Healthpoint | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 427 | RANDOMIZED | PARALLEL | 1PREVENTION | 4QUADRUPLE | false | 0ALL | true | To assess the efficacy of D961H 20 mg once daily (q.d.) versus placebo in continuous treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily Low-dose aspirin therapy by evaluating time from randomisation to occurrence of gastric and/or duodenal ulcers. | null | Prevention | Gastric ulcer Duodenal ulcer Low-dose aspirin | null | 2 | arm 1: Esomeprazole 20mg once daily oral arm 2: Placebo once daily oral | [
0,
2
] | 2 | [
0,
0
] | intervention 1: 20mg, capsule, 72 weeks intervention 2: Placebo, capsule, 72 weeks | intervention 1: Esomeprazole intervention 2: Placebo | 46 | Yotsukaidou | Chiba | Japan | N/A | N/A
Fukui-shi | Fukui | Japan | 136.22257 | 36.06443
Fukuoka | Fukuoka | Japan | 130.41667 | 33.6
Kitakyushu-Shi | Fukuoka | Japan | N/A | N/A
Onga-Gun | Fukuoka | Japan | N/A | N/A
Yukuhashi | Fukuoka | Japan | 130.983 | 33.72873
Fukushima | Fukushima | Japan | 140.46667 | 37.75
Kōr... | 427 | 0 | 0 | 0 | NCT01069939 | 1COMPLETED | 2011-11-01 | 2010-02-01 | AstraZeneca | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 157 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 2MALE | false | This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results. | null | Prostate Cancer | null | 1 | arm 1: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenace of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day inte... | [
0
] | 1 | [
0
] | intervention 1: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injection... | intervention 1: Degarelix 240/80 mg | 11 | Daegu | Daegu | South Korea | 128.59111 | 35.87028
Pyungchon | Gyunggi-do | South Korea | N/A | N/A
Mulgeum-eup | Gyungnam | South Korea | N/A | N/A
Seongnam | N/A | South Korea | 127.39683 | 35.54127
Seoul | N/A | South Korea | 126.9784 | 37.566
Seoul | N/A | South Korea | 126.9784 | 37.566
Seoul | N/A | South Korea |... | 156 | 0 | 0 | 0 | NCT01071915 | 1COMPLETED | 2011-11-01 | 2010-03-01 | Ferring Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 126 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | true | 0ALL | null | Optimal clinical management in early stages of COPD is not established. Tiotropium has been shown to improve exercise tolerance during (CWR) cycle ergometry with GOLD stage II to IV COPD, improvements in constant speed treadmill time in a study of patients who also received pulmonary rehabilitation in a population of p... | null | Pulmonary Disease, Chronic Obstructive | null | 3 | arm 1: Patient to receive 1 tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler arm 2: Patient to receive 1 placebo inhalation powder capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler arm 3: Age and gender matched control subj... | [
1,
2,
4
] | 2 | [
0,
0
] | intervention 1: double blind randomized crossover intervention 2: inhalation powder capsule identical to those containing tiotropium bromide inhalation powder | intervention 1: Tiotropium intervention 2: Placebo | 15 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Jasper | Alabama | United States | -87.27751 | 33.83122
Torrance | California | United States | -118.34063 | 33.83585
Hartford | Connecticut | United States | -72.68509 | 41.76371
Springfield | Illinois | United States | -89.64371 | 39.80172
Muncie | Indiana |... | 244 | 0 | 0 | 0 | NCT01072396 | 1COMPLETED | 2011-11-01 | 2010-02-01 | Boehringer Ingelheim | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 99 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), compared to allopurinol or placebo in patients with excessive amounts of uric acid in their urine and who have recently had kidney stones. | Nephrolithiasis, also called kidney stone disease, occurs in patients with genetic susceptibility and who may have a broad spectrum of metabolic disorders and other comorbid conditions (for example obesity or diabetes). These renal stones develop as a result of supersaturation. Calcium oxalate (CaOx) is the most common... | Hyperuricosuria Kidney Stones | Kidney Calculi Kidney Stones Nephrolithiasis Drug Therapy Uric Acid | null | 3 | arm 1: Febuxostat 80 mg, capsules, orally, once daily for up to 6 months. arm 2: Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months. arm 3: Placebo-matching capsules, orally, once daily for up to 6 months. | [
0,
1,
2
] | 3 | [
0,
0,
0
] | intervention 1: Febuxostat capsules intervention 2: Allopurinol capsules intervention 3: Placebo-matching capsules | intervention 1: Febuxostat intervention 2: Allopurinol intervention 3: Placebo | 28 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Anchorage | Alaska | United States | -149.90028 | 61.21806
Tucson | Arizona | United States | -110.92648 | 32.22174
Costa Mesa | California | United States | -117.91867 | 33.64113
Orange | California | United States | -117.85311 | 33.78779
Palmdale | Californi... | 99 | 0 | 0 | 0 | NCT01077284 | 1COMPLETED | 2011-11-01 | 2010-02-01 | Takeda | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 60 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The purpose of the study is to assess the efficacy and the safety of Chlorhexidine Gluconate chip (Periochip®) versus Placebo Chip in treatment of symptoms in patients with Peri-Implantitis. | This is a Phase 2a study assessing the safety and efficacy of Chlorhexidine Gluconate chip (Periochip®) versus Placebo Chip in treatment of symptoms in patients with Peri-Implantitis | Peri-implantitis | null | 2 | arm 1: PerioChip®, consisting of 2.5 mg Chlorhexidine Gluconate PerioChips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm arm 2: Placebo Chip Placebo Chips were inserted only to target pockets whose pocket depth (PD... | [
0,
2
] | 2 | [
0,
0
] | intervention 1: None intervention 2: None | intervention 1: Chlorhexidine 2.5 mg intervention 2: Placebo chip | 2 | Haifa | N/A | Israel | 34.99928 | 32.81303
Tel Aviv | N/A | Israel | 34.78057 | 32.08088 | 60 | 0 | 0 | 0 | NCT01079663 | 1COMPLETED | 2011-11-01 | 2010-03-01 | Dexcel Pharma Technologies Ltd. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2
] | 35 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to determine whether Vancomycin or Metronidazole is safe and beneficial in the treatment of Primary Sclerosing Cholangitis. | In this protocol, we propose the assessment of potential beneficial effects of the antibiotics vancomycin and metronidazole on liver biochemistries, liver related symptoms and Mayo risk score in patients with PSC. The patients will be randomized into four groups of ten patients: one group will receive low dose vancomyc... | Primary Sclerosing Cholangitis | null | 4 | arm 1: The patients will be randomized into four groups of ten patients: one group will receive low dose vancomycin, one group will receive high dose vancomycin, one group will receive low dose metronidazole and one group will receive high dose metronidazole. arm 2: None arm 3: None arm 4: None | [
0,
0,
0,
0
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: Comparison of different doses of drug intervention 2: Comparison of different doses of drug intervention 3: Comparison of different doses of drug intervention 4: Comparison of different doses of drug intervention 5: Comparison of different drug doses | intervention 1: Vancomycin intervention 2: Vancomycin intervention 3: Metronidazole intervention 4: Metronidazole intervention 5: Vancomycin | 1 | Rochester | Minnesota | United States | -92.4699 | 44.02163 | 35 | 0 | 0 | 0 | NCT01085760 | 1COMPLETED | 2011-11-01 | 2010-02-01 | Mayo Clinic | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 987 | RANDOMIZED | FACTORIAL | 0TREATMENT | 1SINGLE | false | 0ALL | false | Research shows that smoking cessation is the most significant preventable health behavior change that a person can make to lower cancer risk. In addition, telephone quitlines are an effective, science-based smoking cessation treatment that is universally accessible to smokers in the U.S. However, little research has ex... | The study design is a fully crossed 2x2x2 factorial design that tested the effect of two versus six weeks of nicotine replacement therapy (NRT), the effect of NRT monotherapy (nicotine patch alone) versus NRT combination therapy (nicotine patch + oral NRT), and the effect of cognitive medication adherence counseling (C... | Smoking Smoking Cessation | Smoking Smoking cessation Medication adherence | null | 8 | arm 1: Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)
2 Weeks of Nicotine patch dosed as follows:
If \> 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks
If \< or = 10 cigs/day: one 14 mg nicotine ... | [
1,
1,
1,
1,
1,
1,
1,
1
] | 3 | [
0,
0,
5
] | intervention 1: If \> 10 cigs/day: one 21 mg nicotine patch per day
If \< or = 10 cigs/day: one 14 mg nicotine patch per day intervention 2: If \< 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.
I... | intervention 1: Nicotine patch intervention 2: Nicotine gum intervention 3: CMAC | 2 | Seattle | Washington | United States | -122.33207 | 47.60621
Madison | Wisconsin | United States | -89.40123 | 43.07305 | 987 | 0 | 0 | 0 | NCT01087905 | 1COMPLETED | 2011-11-01 | 2010-04-01 | University of Wisconsin, Madison | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 811 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | This study will investigate the efficacy of a combination treatment of duloxetine + pregabalin compared with the maximal dose of each drug in monotherapy, in patients with diabetic peripheral neuropathic pain (DPNP) who have not responded to the standard recommended dose of either drug. It will provide an answer to a c... | null | Diabetic Neuropathy, Painful | null | 4 | arm 1: Initial Treatment:
Duloxetine 30 milligram (mg) daily for 1 week
Duloxetine 60 mg daily for 7 weeks
Intensive Treatment:
Duloxetine 90 mg (60 mg in the morning, 30 mg in the evening) daily for 1 week
Duloxetine 120 mg (60 mg twice daily) daily for 7 weeks arm 2: Initial Treatment:
Pregabalin 150 mg daily f... | [
0,
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: Administered orally intervention 2: Administered orally intervention 3: Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks | intervention 1: Duloxetine intervention 2: Pregabalin intervention 3: Placebo | 54 | Newcastle | New South Wales | Australia | 151.7801 | -32.92953
Warrawong | New South Wales | Australia | 150.88833 | -34.485
Elizabeth Vale | South Australia | Australia | 138.66819 | -34.74857
Kelowna | British Columbia | Canada | -119.48568 | 49.88307
Vancouver | British Columbia | Canada | -123.11934 | 49.24966
Winn... | 1,143 | 0 | 0 | 0 | NCT01089556 | 1COMPLETED | 2011-11-01 | 2010-03-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 19 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | RATIONALE: Ritonavir and lopinavir may stop the growth of gliomas by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well giving ritonavir together with lopinavir works in treating patients with progressive or recurrent high-grade... | PRIMARY OBJECTIVES: I. To evaluate the 6-month progression-free survival in patients with recurrent or progressive high grade gliomas treated with ritonavir and lopinavir. SECONDARY OBJECTIVES: I. To evaluate the toxicity of ritonavir and lopinavir in this patient population. OUTLINE: Patients receive oral ritonavir an... | Brain Tumor Anaplastic Astrocytoma Anaplastic Ependymoma Anaplastic Oligodendroglioma Brain Stem Glioma Giant Cell Glioblastoma Glioblastoma Gliosarcoma Mixed Glioma | adult brain tumor adult anaplastic astrocytoma adult anaplastic ependymoma adult anaplastic oligodendroglioma adult brain stem glioma adult giant cell glioblastoma adult glioblastoma adult gliosarcoma adult mixed glioma recurrent adult brain tumor | null | 1 | arm 1: Patients receive oral ritonavir and lopinavir twice daily in the absence of disease progression or unacceptable toxicity. | [
0
] | 2 | [
0,
0
] | intervention 1: Given orally intervention 2: Given orally | intervention 1: ritonavir intervention 2: lopinavir | 1 | Cleveland | Ohio | United States | -81.69541 | 41.4995 | 19 | 0 | 0 | 0 | NCT01095094 | 6TERMINATED | 2011-11-01 | 2009-01-01 | Case Comprehensive Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 20 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | Effectiveness of Floseal for the treatment of posterior epistaxis. | Floseal, a hemostatic agent, is an effective treatment for anterior epistaxis as well as numerous other acute bleeding conditions throughout the body. The investigators hypothesize that Floseal is an effective treatment for posterior epistaxis. If so, then this will also lead to significant cost savings in comparison t... | Epistaxis | Posterior Epistaxis | null | 1 | arm 1: Received 1 syringe of Floseal for treatment of posterior epistaxis. | [
0
] | 1 | [
0
] | intervention 1: Received 1 syringe of Floseal as treatment for posterior epistaxis. | intervention 1: Floseal | 0 | null | 20 | 0 | 0 | 0 | NCT01098578 | 1COMPLETED | 2011-11-01 | 2010-04-01 | Ottawa Hospital Research Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 570 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 1FEMALE | false | To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause | The study is a 24-week, multicenter, double-blind, randomized, placebo-controlled study of Brisdelle (paroxetine mesylate) Capsules 7.5 mg in subjects with moderate to severe postmenopausal VMS, defined as follows:
1. Moderate VMS: Sensation of heat with sweating, able to continue activity
2. Severe VMS: Sensation of ... | Hot Flashes | Vasomotor Symptoms Menopause Hot Flashes Perimenopause Nonhormonal therapies Climacteric symptoms Mesafem Low-Dose Mesylate salt of Paroxetine (LDMP) | null | 2 | arm 1: Brisdelle (paroxetine mesylate) arm 2: Sugar pill | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio. intervention 2: Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio. | intervention 1: Brisdelle (paroxetine mesylate) intervention 2: Placebo capsules | 32 | Montgomery | Alabama | United States | -86.29997 | 32.36681
Chandler | Arizona | United States | -111.84125 | 33.30616
San Diego | California | United States | -117.16472 | 32.71571
Santa Ana | California | United States | -117.86783 | 33.74557
Denver | Colorado | United States | -104.9847 | 39.73915
Waterbury | Connec... | 570 | 0 | 0 | 0 | NCT01101841 | 1COMPLETED | 2011-11-01 | 2010-03-01 | Noven Therapeutics | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 4 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to determine whether the cell therapy with bone marrow mononuclear cells is safe in the treatment of chronic obstructive pulmonary disease, specifically the pulmonary emphysema. | The main feature of the pulmonary emphysema, included in range of the Chronic Obstructive Pulmonary Disease (COPD), is the airflow obstruction resulting from the destruction of the alveolar walls distal to the terminal bronchiole, without significant pulmonary fibrosis. The existing clinical approaches has contributed ... | Chronic Obstructive Pulmonary Disease Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease Emphysema Cell therapy Bone marrow mononuclear cells stem cells | null | 2 | arm 1: emphysema patients evaluated prior to the stem cells infusion arm 2: emphysema patients evaluated 30 days after the stem cells infusion | [
1,
0
] | 3 | [
0,
3,
6
] | intervention 1: Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure. intervention 2: pullout of 200ml of bone marrow through the puncture of the iliac crest intervention 3: slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline. | intervention 1: Stem cells stimulation intervention 2: stem cells collection intervention 3: stem cells infusion | 1 | Assis | São Paulo | Brazil | -50.41222 | -22.66167 | 4 | 0 | 0 | 0 | NCT01110252 | 1COMPLETED | 2011-11-01 | 2009-05-01 | UPECLIN HC FM Botucatu Unesp | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 282 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This study will evaluate the use of a prasugrel 60 mg loading dose (LD) administered during percutaneous coronary intervention (PCI) with and without a prior LD of clopidogrel on platelet inhibition in patients presenting with acute coronary syndrome (ACS). Platelet inhibition following a prasugrel LD in clopidogrel pr... | null | Acute Coronary Syndrome | Plavix, Effient | null | 3 | arm 1: Placebo loading dose administered once orally before percutaneous coronary intervention (PCI) and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours. arm 2: 600-mg clopido... | [
2,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours. intervention 2: Loading dose administered once orally. intervention 3: Loading dose administered once orally | intervention 1: Prasugrel intervention 2: Clopidogrel intervention 3: Placebo | 3 | Bangalore | N/A | India | 77.59369 | 12.97194
Hyderabaad | N/A | India | N/A | N/A
New Delhi | N/A | India | 77.2148 | 28.62137 | 276 | 0 | 0 | 0 | NCT01115738 | 1COMPLETED | 2011-11-01 | 2010-05-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 6 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 2MALE | true | The purpose of this research study is to assess the effects of ZD4054 on prostate cancer that has spread to the bones by using new imaging techniques. In particular, this study will use fluorodeoxyglucose (FDG) and 18F-Sodium Fluoride (NaF) PET/computed tomography (CT) and MRI scans to look for changes in bone metastas... | null | Prostate Cancer | Metastatic castrate-resistant prostate cancer bone metastasis | null | 1 | arm 1: ZD4054 + multimodal PET/MRI imaging | [
0
] | 1 | [
0
] | intervention 1: All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 wee... | intervention 1: ZD4054 | 1 | Madison | Wisconsin | United States | -89.40123 | 43.07305 | 6 | 0 | 0 | 0 | NCT01119118 | 6TERMINATED | 2011-11-01 | 2010-04-01 | University of Wisconsin, Madison | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 211 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | null | This is a 52-week, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily NVA237, using tiotropium as an active control, in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD) . | null | Chronic Obstructive Pulmonary Disease | COPD NVA237 | null | 2 | arm 1: 50µg once daily arm 2: 18µg once daily | [
0,
0
] | 2 | [
0,
0
] | intervention 1: 50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®) intervention 2: 18µg capsules for inhalation, delivered via HandiHaler® | intervention 1: NVA237 intervention 2: Tiotropium | 40 | Fukuoka | Fukuoka | Japan | 130.41667 | 33.6
Iizuka | Fukuoka | Japan | 130.68678 | 33.63654
Kitakyushu | Fukuoka | Japan | 130.85034 | 33.85181
Kitakyushu | Fukuoka | Japan | 130.85034 | 33.85181
Kurume | Fukuoka | Japan | 130.51667 | 33.31667
Ōnojō | Fukuoka | Japan | 130.47861 | 33.53567
Yanagawa | Fukuoka | Japan |... | 163 | 0 | 0 | 0 | NCT01119937 | 1COMPLETED | 2011-11-01 | 2010-05-01 | Novartis Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 16 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to compare the use of insulin glargine plus insulin lispro to human regular insulin for treatment of hyperglycemia in the hospital setting in patients without known prior history of diabetes. | This study involves a comparison of 2 methods for administering subcutaneous insulin therapy to non-critically ill adult patients with hyperglycemia and without known history of diabetes who are admitted to non-intensive care unit (ICU) general medical hospital services. Basal-bolus therapy, considered the gold standar... | Hyperglycemia | Hyperglycemia Diabetes Hospital Diabetic | null | 2 | arm 1: None arm 2: None | [
1,
0
] | 3 | [
0,
0,
0
] | intervention 1: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization) intervention 2: Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 day... | intervention 1: Human regular insulin intervention 2: Insulin lispro intervention 3: Insulin glargine | 12 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Jacksonville | Florida | United States | -81.65565 | 30.33218
Miami | Florida | United States | -80.19366 | 25.77427
Weston | Florida | United States | -80.39977 | 26.10037
Atlanta | Georgia | United States | -84.38798 | 33.749
Topeka | Kansas | United States ... | 16 | 0 | 0 | 0 | NCT01136746 | 6TERMINATED | 2011-11-01 | 2011-03-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 65 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 2MALE | false | This trial is conducted in Asia, Europe, and North and South America. The aim of this clinical trial is to investigate the safety and efficacy of turoctocog alfa (recombinant factor VIII, rFVIII (N8)) in male previously treated paediatric subjects with haemophilia A. | null | Congenital Bleeding Disorder Haemophilia A | null | 1 | arm 1: None | [
0
] | 2 | [
0,
0
] | intervention 1: Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen. intervention 2: Subjects will undergo half-life evaluation of their current factor VIII product... | intervention 1: turoctocog alfa intervention 2: turoctocog alfa | 38 | Phoenix | Arizona | United States | -112.07404 | 33.44838
Orange | California | United States | -117.85311 | 33.78779
Torrance | California | United States | -118.34063 | 33.83585
Tampa | Florida | United States | -82.45843 | 27.94752
Augusta | Georgia | United States | -81.97484 | 33.47097
Iowa City | Iowa | United St... | 63 | 0 | 0 | 0 | NCT01138501 | 1COMPLETED | 2011-11-01 | 2010-06-01 | Novo Nordisk A/S | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 17 | RANDOMIZED | FACTORIAL | 9OTHER | 0NONE | true | 0ALL | true | The purpose of this study is to non-invasively study the reflective changes in cardiac output as response to fluid therapy in the pediatric moderate hypovolemia/dehydrated pediatric patients using sub-q rehydration using Hylenex augmented subcutaneous infusion of fluids and electrolytes compared to intravenous methods. | This is an open-labeled, single-center Phase IV clinical trial. The study will consist of patients with moderate hypovolemia/dehydration requiring parenteral rehydration. It is expected that this study will describe the onset or change in cardiac output using Hylenex augmented subcutaneous rehydration from ages 2 month... | Dehydration Cardiac Output Pediatrics | cardiac output dehydration pediatrics | null | 2 | arm 1: control arm of the study arm 2: 1ml subcutaneous with initiation of intravenous fluids then every 24 hours with a maximum dose of 3 injections in 72 hours | [
4,
0
] | 1 | [
0
] | intervention 1: 1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours | intervention 1: Hylenex | 1 | Nashville | Tennessee | United States | -86.78444 | 36.16589 | 0 | 0 | 0 | 0 | NCT01139294 | 1COMPLETED | 2011-11-01 | 2010-02-01 | Vanderbilt University Medical Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 149 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long-term safety and tol... | null | Schizophrenia Schizoaffective Disorder | Schizophrenia Lurasidone Latuda | null | 1 | arm 1: Subjects will continue on treatment with the same dose of lurasidone flexible dosing - 40 mg to 12 mg once daily taken orallay at endpoint of the D1050289 ( NCT01143077) core study. | [
0
] | 1 | [
0
] | intervention 1: 40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months | intervention 1: Lurasidone HCl | 27 | Little Rock | Arkansas | United States | -92.28959 | 34.74648
Escondido | California | United States | -117.08642 | 33.11921
Garden Grove | California | United States | -117.94145 | 33.77391
Oakland | California | United States | -122.2708 | 37.80437
Paramount | California | United States | -118.15979 | 33.88946
Pasade... | 148 | 0 | 0 | 0 | NCT01143090 | 1COMPLETED | 2011-11-01 | 2010-08-01 | Sumitomo Pharma America, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 19 | RANDOMIZED | PARALLEL | 0TREATMENT | 1SINGLE | false | 0ALL | true | Multiple Sclerosis (MS) is the most common neurological disorder causing disability in young adults. The management of MS-patients requires treatment with disease-modifying agents, monoclonal antibodies such as natalizumab or immunosuppressants. Natalizumab showed good efficacy and is approved for treatment of relapsin... | At present, there is no cure for multiple sclerosis and the management of MS-patients requires treatment with disease-modifying agents such as interferon-beta or glatiramer acetate, monoclonal antibodies such as natalizumab or immunsuppressants such as mitoxantrone, azathioprine or methotrexate. Acute relapses are usua... | Relapsing-remitting Multiple Sclerosis | Natalizumab Interferon-beta 1b De-escalation Ticino | null | 2 | arm 1: Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions. arm 2: 250 mcg (8 MIU) ... | [
1,
0
] | 2 | [
0,
0
] | intervention 1: Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwis... | intervention 1: interferon beta-1b intervention 2: Natalizumab | 1 | Lugano | Canton Ticino | Switzerland | 8.96004 | 46.01008 | 19 | 0 | 0 | 0 | NCT01144052 | 1COMPLETED | 2011-11-01 | 2010-06-01 | Claudio Gobbi | 2OTHER_GOV | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 24 | RANDOMIZED | PARALLEL | 0TREATMENT | 1SINGLE | false | 0ALL | false | Exenatide has been shown to result in better glycemic control in type II diabetes patients. Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to decreased inflammation by virtue of better glycemic control and weight loss.
The purpose of this study is to determine if the addition ... | null | Type 2 Diabetes | type 2 diabetes obesity | null | 3 | arm 1: exenatide 5 mcg arm 2: exenatide 10 mcg arm 3: placebo | [
0,
0,
2
] | 3 | [
0,
0,
0
] | intervention 1: exenatide 5 mcg intervention 2: exenatide 10 mcg intervention 3: saline sq | intervention 1: exenatide 5 mcg intervention 2: exenatide 10 mcg intervention 3: placebo | 1 | Buffalo | New York | United States | -78.87837 | 42.88645 | 24 | 0 | 0 | 0 | NCT01154933 | 1COMPLETED | 2011-11-01 | 2008-04-01 | University at Buffalo | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 319 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant. | A multicenter, randomized, double-blind, parallel group, placebo-controlled, phase III efficacy and safety study of TC-5214 (S-mecamylamine) in flexible doses as an adjunct to an antidepressant in patients with major depressive disorder with an inadequate response to antidepressant therapy. | Major Depressive Disorder Depression | Major Depressive Disorder MDD Depression Safety add-on therapy | null | 2 | arm 1: Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID arm 2: Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Tablet, oral, twice daily for 8 weeks intervention 2: Tablet, oral, twice daily for 8 weeks | intervention 1: TC-5214 intervention 2: Placebo | 51 | Tuscaloosa | Alabama | United States | -87.56917 | 33.20984
Tucson | Arizona | United States | -110.92648 | 32.22174
Little Rock | Arkansas | United States | -92.28959 | 34.74648
Chino | California | United States | -117.68894 | 34.01223
Costa Mesa | California | United States | -117.91867 | 33.64113
Encino | Californi... | 316 | 0 | 0 | 0 | NCT01157078 | 1COMPLETED | 2011-11-01 | 2010-06-01 | AstraZeneca | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 410 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 2MALE | false | The primary purpose of the study is to compare the efficacy of LY2452473 + tadalafil to tadalafil alone in improving the erectile function (EF) of men with erectile dysfunction (ED) who incompletely respond to tadalafil alone. | null | Erectile Dysfunction | null | 5 | arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None | [
0,
0,
0,
1,
1
] | 4 | [
0,
0,
0,
0
] | intervention 1: Administered orally, once daily for 12 weeks intervention 2: Administered orally, once daily for 12 weeks intervention 3: Administered orally, once daily for 12 weeks intervention 4: Administered orally, once daily for 12 weeks | intervention 1: LY2452473 intervention 2: tadalafil intervention 3: placebo (tadalafil) intervention 4: placebo (LY2452473) | 36 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Phoenix | Arizona | United States | -112.07404 | 33.44838
Glendora | California | United States | -117.86534 | 34.13612
Irvine | California | United States | -117.82311 | 33.66946
Long Beach | California | United States | -118.18923 | 33.76696
Newport Beach | ... | 941 | 0 | 0 | 0 | NCT01160289 | 1COMPLETED | 2011-11-01 | 2010-10-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 203 | NA | SINGLE_GROUP | 2DIAGNOSTIC | 0NONE | false | 0ALL | false | To determine the level of association between quantitative regional estimates of brain uptake of \[18F\]flutemetamol and quantitative immunohistochemical regional estimates of brain levels of amyloid estimated from post-mortem analysis of corresponding brain tissue samples. | null | Brain Fibrillarab Levels | Amyloid PET-Positron Emission Tomography SUVR-Standard uptake value ratios | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection. | intervention 1: [18F] Flutemetamol | 1 | Princeton | New Jersey | United States | -74.65905 | 40.34872 | 180 | 0 | 0 | 0 | NCT01165554 | 1COMPLETED | 2011-11-01 | 2010-05-01 | GE Healthcare | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 17 | RANDOMIZED | PARALLEL | null | 0NONE | false | 0ALL | false | In the treatment of patients with candidemia and/or other forms of invasive candidiasis , Anidulafungin is at least as effective and safe as Fluconazole. | To support anidulafungin NDA in China Due to the challenges in subject recruitment resulting in protracted study course, Pfizer Inc. has decided to terminate trial A8851023 prematurely based on the recommendation by the senior management team on November 8, 2011. The decision to terminate the trial was not based on any... | Candidemia | Phase 3b Efficacy and Safety evaluation of Anidulafungin ICC | null | 1 | arm 1: None | [
1
] | 1 | [
0
] | intervention 1: Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days | intervention 1: Anidulafungin/Fluconazole | 7 | Guangzhou | Guangdong | China | 113.25 | 23.11667
Nanjing | Jiangsu | China | 118.77778 | 32.06167
Shanghai | Shanghai Municipality | China | 121.45806 | 31.22222
Hangzhou | Zhejiang | China | 120.16142 | 30.29365
Hangzhou | Zhejiang | China | 120.16142 | 30.29365
Beijing | N/A | China | 116.39723 | 39.9075
Shanghai | ... | 17 | 0 | 0 | 0 | NCT01176058 | 6TERMINATED | 2011-11-01 | 2010-12-01 | Pfizer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 2 | NA | SINGLE_GROUP | 7BASIC_SCIENCE | 0NONE | false | 1FEMALE | false | This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue. The investigators will do this by comparing tissues from the original breast biopsy to tissues obtained after taking vorinostat and tamoxifen for 2 ... | Key eligibility criteria include:
* Newly diagnosed invasive breast cancer awaiting surgery or neoadjuvant (preoperative) treatment
* No use of hormone contraceptives or replacement therapy within 30 days prior to the diagnostic breast cancer biopsy (unless willing to have an additional biopsy prior to starting the st... | Stage I Breast Cancer Stage II Breast Cancer Stage III Breast Cancer Invasive Breast Cancer | Preoperative Neoadjuvant | null | 1 | arm 1: Vorinostat and tamoxifen are taken for about 14 days prior to definitive surgery. | [
0
] | 1 | [
0
] | intervention 1: vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days | intervention 1: Vorinostat and Tamoxifen | 1 | Baltimore | Maryland | United States | -76.61219 | 39.29038 | 2 | 0 | 0 | 0 | NCT01194427 | 6TERMINATED | 2011-11-01 | 2011-03-01 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 21 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to explore the effect of treating actinic keratoses of the face with imiquimod 3.75% cream followed by photodynamic therapy in comparison to treatment with imiquimod alone | Actinic keratoses are common skin lesions associated with solar ultraviolet radiation exposure. Some actinic keratoses may develop into skin cancers.
Imiquimod 3.75% cream is an approved treatment for actinic keratoses that utilizes a regimen of application to the entire face or balding scalp of up to 2 packets of cre... | Actinic Keratosis | Imiquimod Photodynamic therapy Actinic keratoses Sequential therapy Therapeutic uses | null | 2 | arm 1: Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light arm 2: Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-w... | [
0,
1
] | 2 | [
0,
0
] | intervention 1: Administered 4 weeks after completion of imiquimod therapy intervention 2: Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation | intervention 1: Photodynamic therapy intervention 2: Imiquimod | 3 | Englewood | Colorado | United States | -104.98776 | 39.64777
Charlotte | North Carolina | United States | -80.84313 | 35.22709
Nashville | Tennessee | United States | -86.78444 | 36.16589 | 21 | 0 | 0 | 0 | NCT01203878 | 6TERMINATED | 2011-11-01 | 2010-09-01 | Tennessee Clinical Research Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 416 | RANDOMIZED | PARALLEL | 2DIAGNOSTIC | 4QUADRUPLE | false | 0ALL | false | The purpose of this study is to look at the safety (what are the side effects)and efficacy (how well does it work) of Dotarem® when used in taking images of the brain / spine. The results will be compared to the results of MRI taken without Dotarem. | This is a study involving the use of Magnetic Resonance Imaging (MRI) contrast agents called Dotarem®. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Dotarem® when used for taking images of the brain and spine. The results of the MRI will be compar... | Diagnostic Self Evaluation Central Nervous System Diseases | CNS Contrast Agent MRI Dotarem Magnevist | null | 3 | arm 1: Dotarem and Magnevist were randomised as 2:1 ratio for adult patients. arm 2: Dotarem and Magnevist were randomised as 2:1 ratio arm 3: Pediatric patients were assigned to Dotarem group only. | [
0,
1,
0
] | 2 | [
0,
0
] | intervention 1: 0.1 mmol/kg by body weight, single IV injection intervention 2: 0.1 mmol/kg by body weight, single IV injection | intervention 1: Dotarem (gadoterate meglumine) intervention 2: Magnevist (gadopentetate dimeglumine) | 52 | Birmingham | Alabama | United States | -86.80249 | 33.52066
Tucson | Arizona | United States | -110.92648 | 32.22174
Tucson | Arizona | United States | -110.92648 | 32.22174
Indian Wells | California | United States | -116.34311 | 33.71791
Hollywood | Florida | United States | -80.14949 | 26.0112
Chicago | Illinois | U... | 395 | 0 | 0 | 0 | NCT01211873 | 1COMPLETED | 2011-11-01 | 2010-09-01 | Guerbet | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 154 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The primary objective of the study was to evaluate the proportion of subjects with a bowel movement (BM) without straining or without hard and/or lumpy stool within the first 24 h of treatment for subjects taking 1 of 3 single doses of Polyethylene Glycol (PEG) plus Electrolytes (PEG+E) (13.125 g, 26.25 g, 39.375 g). T... | null | Constipation | null | 3 | arm 1: Single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time arm 2: Two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time arm 3: Three sachets of PEG+E (39.375 g) dissol... | [
0,
0,
0
] | 1 | [
0
] | intervention 1: 13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes | intervention 1: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430) | 1 | Cork | N/A | Ireland | -8.47061 | 51.89797 | 154 | 0 | 0 | 0 | NCT01212445 | 1COMPLETED | 2011-11-01 | 2010-10-01 | Bayer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | |
[
3,
4
] | 78 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | true | This study will investigate how the levels of a repeat dose of CTAP101 changes in the body over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances (pharmacodynamics, PD) in patients with chronic kidney disease (CKD, vitamin D insufficiency and secondary hyperparathyroidism (SHPT). | null | Chronic Kidney Disease Secondary Hyperparathyroidism Vitamin D Insufficiency | Parathyroid Diseases Renal Insufficiency Kidney Failure, Chronic Hyperparathyroidism, Secondary Vitamin D Hyperparathyroidism Kidney Diseases Kidney Failure Renal Insufficiency, Chronic | null | 5 | arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None | [
0,
0,
2,
0,
2
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: 60µg of CTAP101 capsules given once daily for 42 days. intervention 2: 90µg of CTAP101 capsules given once daily for 42 days. intervention 3: Placebo capsules given once daily for 42 days. intervention 4: 30µg of CTAP101 capsules given once daily for 42 days. intervention 5: Placebo capsules given once ... | intervention 1: Cohort 1 CTAP101 Capsules- 60µg intervention 2: Cohort 1 CTAP101 Capsules - 90µg intervention 3: Cohort 1 Matching Sugar Capsule intervention 4: Cohort 2 CTAP101 Capsules - 30µg intervention 5: Cohort 2 Matching Sugar Capsule | 1 | Bannockburn | Illinois | United States | -87.86646 | 42.19336 | 77 | 0 | 0 | 0 | NCT01219855 | 1COMPLETED | 2011-11-01 | 2010-10-01 | OPKO Health, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 |
[
3
] | 154 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | false | 0ALL | null | The purpose of this study is compare the effect of different doses of tiotropium delivered by the HandiHaler and Respimat device on lung function. Additionally, the study will investigate the pharmacokinetic profile of these different doses. Studying the pharmacokinetic profile shows what happens to the medication in t... | null | Pulmonary Disease, Chronic Obstructive | null | 5 | arm 1: Tiotropium inhalation solution low dose arm 2: Tiotropium inhalation solution medium dose arm 3: Tiotropium inhalation solution high dose arm 4: Tiotropium inhalation powder 18mcg arm 5: Placebo inhalation solution | [
0,
0,
0,
1,
2
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: Tiotropium inhalation solution medium dose intervention 2: Tiotropium inhalation solution low dose intervention 3: Tiotropium inhalation solution high dose intervention 4: Tiotropium inhalation powder 18mcg intervention 5: Placebo inhalation solution | intervention 1: Tiotropium medium intervention 2: Tiotropium low intervention 3: Tiotropium high intervention 4: Tiotropium 18mcg intervention 5: Tiotropium placebo | 11 | Genk | N/A | Belgium | 5.50082 | 50.965
Ghent | N/A | Belgium | 3.71667 | 51.05
Hasselt | N/A | Belgium | 5.33781 | 50.93106
Copenhagen K | N/A | Denmark | N/A | N/A
København NV | N/A | Denmark | 12.52343 | 55.71258
Odense C | N/A | Denmark | 10.39538 | 55.40841
Helsinki | N/A | Finland | 24.93545 | 60.16952
Tampere |... | 735 | 0 | 0 | 0 | NCT01222533 | 1COMPLETED | 2011-11-01 | 2010-10-01 | Boehringer Ingelheim | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2
] | 24 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | Yearly in the United States over 500,000 newborns are delivered prematurely. This population is at high risk of catastrophic bowel disease known as necrotizing enterocolitis. Infants with necrotizing enterocolitis are at high risk of death, and survivors are at increased risk of mental retardation. Metronidazole is an ... | null | Serious Systemic Infections Necrotizing Enterocolitis | Metronidazole Neonate Premature Sepsis Necrotizing enterocolitis | null | 1 | arm 1: Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours | [
0
] | 1 | [
0
] | intervention 1: Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with \>=14 postnatal days and every 24 hours for infants \<14 postnatal days. | intervention 1: Metronidazole | 3 | Orange | California | United States | -117.85311 | 33.78779
Wichita | Kansas | United States | -97.33754 | 37.69224
Durham | North Carolina | United States | -78.89862 | 35.99403 | 24 | 0 | 0 | 0 | NCT01222585 | 1COMPLETED | 2011-11-01 | 2011-01-01 | Michael Cohen-Wolkowiez | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 268 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 1FEMALE | false | A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the safety and efficacy of desmopressin oral melt tablets against placebo during 3 months of treatment in adult females with nocturia. | null | Nocturia | null | 2 | arm 1: Participants took 1 orally disintegrating tablet of desmopressin 25 μg every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period. arm 2: Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour before bedtime for the entire duratio... | [
0,
2
] | 2 | [
0,
0
] | intervention 1: None intervention 2: None | intervention 1: Desmopressin intervention 2: Placebo | 45 | Huntsville | Alabama | United States | -86.58594 | 34.7304
Scottsdale | Arkansas | United States | N/A | N/A
Foothill Ranch | California | United States | -117.66088 | 33.68641
Los Angeles | California | United States | -118.24368 | 34.05223
Santa Rosa | California | United States | -122.71443 | 38.44047
Denver | Color... | 261 | 0 | 0 | 0 | NCT01223937 | 1COMPLETED | 2011-11-01 | 2010-11-01 | Ferring Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
0
] | 28 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this study is to evaluate the effects of the amino acid supplement N-Acetylcysteine versus placebo on working memory and other cognitive functions in persons with a diagnosis of schizophrenia. | Working memory impairment in Schizophrenia is produced by deficiencies of feedback inhibition of glutamate release, due to low cysteine-glutamate antiporter activity. Because of this mechanism, we are interested in whether acute administration of N-Acetylcysteine will improve performance of patients with schizophrenia ... | Schizophrenia | Schizophrenia working memory N-Acetylcysteine | null | 2 | arm 1: Group A first receives the commercially available sustained release form of N-acetylcysteine, then the matching placebo capsules both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days). arm 2:... | [
0,
2
] | 2 | [
7,
0
] | intervention 1: N-acetylcysteine 1200mg bid for 3 days intervention 2: Placebo | intervention 1: N-Acetylcysteine intervention 2: Placebo | 1 | New Haven | Connecticut | United States | -72.92816 | 41.30815 | 45 | 0 | 0 | 0 | NCT01232790 | 1COMPLETED | 2011-11-01 | 2010-02-01 | Yale University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 42 | RANDOMIZED | PARALLEL | 7BASIC_SCIENCE | 0NONE | true | 1FEMALE | false | This pilot study is being performed to investigate the influence that starting contraception with an IUD has on the local immune cell populations and features, with a particular focus on the cells and cell-surface features that are important in HIV transmission (CD4 cells and CCR5 cell receptors).
Based on results fro... | null | Genital Tract Mucosal Immunity Genital Tract Microflora | intrauterine device IUD levonorgestrel copper CD4 CCR5 microflora | null | 3 | arm 1: Healthy volunteers not at risk of pregnancy and not using any hormonal contraception. arm 2: Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS. arm 3: Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD. | [
4,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD ... | intervention 1: IUD placement intervention 2: Levonorgestrel IUD intervention 3: Copper T380A IUD | 1 | Pittsburgh | Pennsylvania | United States | -79.99589 | 40.44062 | 42 | 0 | 0 | 0 | NCT01240811 | 1COMPLETED | 2011-11-01 | 2010-11-01 | Sharon Achilles | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2
] | 9 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this study is to assess the safety and tolerability of LY2584702 in Japanese patients with advanced and/or metastatic solid tumors for which no proven effective therapy exists. | null | Cancer | Advanced Cancer Metastatic Cancer p70s6 inhibitor | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: Dose escalation starting at 50 milligram (mg). On Day 1, subjects will receive a single oral dose. After a two-day observation period, subjects will receive oral doses twice daily for a 28-day cycle.
Patients may continue 28-day cycles of twice daily dosing until discontinuation criteria are met. | intervention 1: LY2584702 | 1 | Chiba | N/A | Japan | 140.11667 | 35.6 | 9 | 0 | 0 | 0 | NCT01241461 | 1COMPLETED | 2011-11-01 | 2010-11-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 248 | RANDOMIZED | PARALLEL | 1PREVENTION | 4QUADRUPLE | false | 0ALL | true | The routine administration of 75 mg of intravenous aminophylline following regadenoson (Lexiscan®), a commonly used medication for nuclear stress testing of the heart, can reduce the gastrointestinal (diarrhea and stomach upset) and other side effects related to regadenoson. | Approximately 250 patients who are referred for a nuclear stress testing of the heart with regadenoson (Lexiscan®) will be recruited to participate in the study. Following regadenoson (administered as part of a stress routine test protocol) participants will receive either aminophylline (75 mg - intravenously) or a mat... | Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan | regadenoson lexiscan aminophylline SPECT Myocardial Perfusion Imaging pharmacologic stress test | null | 2 | arm 1: 75 mg of intravenous aminophylline. arm 2: Matching normal saline placebo (sterile salt water). | [
0,
2
] | 2 | [
0,
0
] | intervention 1: 75 mg of intravenous aminophylline intervention 2: Matching 0.9 Normal Saline (sterile salt water)administered intravenously. | intervention 1: Aminophylline intervention 2: Placebo | 1 | Chicago | Illinois | United States | -87.65005 | 41.85003 | 248 | 0 | 0 | 0 | NCT01250496 | 6TERMINATED | 2011-11-01 | 2010-11-01 | Rush University Medical Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2
] | 26 | NON_RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | true | 0ALL | false | The primary purpose of this study is to help answer the following research questions, and not to provide treatment for any condition:
* To evaluate how much of the study drug (LY2189265) is in the blood of participants with varying degrees of liver impairment compared to those with normal liver function.
* To assess t... | null | Diabetes Mellitus, Type 2 | null | 4 | arm 1: LY2189265: A single, subcutaneous (SC) 1.5-milligram (mg) injection on Day 1 in participants with normal hepatic function arm 2: LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with mild hepatic impairment (Child-Pugh A) arm 3: LY2189265: A single, SC 1.5-mg injection on Day 1 in participants w... | [
0,
0,
0,
0
] | 1 | [
0
] | intervention 1: Subcutaneous (SC) injection | intervention 1: LY2189265 | 2 | Munich | N/A | Germany | 11.57549 | 48.13743
Budapest | N/A | Hungary | 19.04045 | 47.49835 | 26 | 0 | 0 | 0 | NCT01253304 | 1COMPLETED | 2011-11-01 | 2010-11-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 255 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 1FEMALE | true | The purpose of this Phase III trial is to confirm the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy. | null | Vaginal Atrophy | Vulvar/vaginal atrophy Atrophic Vaginitis Dehydroepiandrosterone DHEA Prasterone Vaginorm Menopause Intrarosa | null | 3 | arm 1: None arm 2: None arm 3: None | [
2,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: Placebo vaginal suppository intervention 2: Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks. intervention 3: Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks. | intervention 1: Placebo intervention 2: DHEA intervention 3: DHEA | 33 | Montgomery | Alabama | United States | -86.29997 | 32.36681
Tucson | Arizona | United States | -110.92648 | 32.22174
Sacramento | California | United States | -121.4944 | 38.58157
San Diego | California | United States | -117.16472 | 32.71571
San Diego | California | United States | -117.16472 | 32.71571
Denver | Color... | 253 | 0 | 0 | 0 | NCT01256684 | 1COMPLETED | 2011-11-01 | 2010-12-01 | EndoCeutics Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 21 | RANDOMIZED | CROSSOVER | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | The purpose of this study is to evaluate the effect of ivacaftor (VX-770) on lung clearance index (LCI) in subjects aged 6 years and older with cystic fibrosis (CF) who have the G551D-CFTR mutation on at least 1 allele. | Currently, limited objective measures are available to quantify lung function in CF patients with mild lung disease. Lung clearance index (LCI) derived from inert gas multiple-breath washout (MBW) testing hold considerable promise to evaluate early lung disease as studies have detected abnormalities in a high percentag... | Cystic Fibrosis | null | 2 | arm 1: Ivacaftor administered in Treatment Period 1 and placebo administered in Treatment Period 2. arm 2: Placebo administered in Treatment Period 1 and ivacaftor administered in Treatment Sequence 2. | [
0,
0
] | 2 | [
0,
0
] | intervention 1: 150 mg tablet, oral use, twice daily every 12 hours (q12h) intervention 2: Tablet, oral use, twice daily every 12 hours (q12h) | intervention 1: Ivacaftor intervention 2: Placebo | 8 | Stanford | California | United States | -122.16608 | 37.42411
Iowa City | Iowa | United States | -91.53017 | 41.66113
Durham | North Carolina | United States | -78.89862 | 35.99403
Pittsburgh | Pennsylvania | United States | -79.99589 | 40.44062
Toronto | Ontario | Canada | -79.39864 | 43.70643
Belfast | N/A | United K... | 37 | 0 | 0 | 0 | NCT01262352 | 1COMPLETED | 2011-11-01 | 2011-01-01 | Vertex Pharmaceuticals Incorporated | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 113 | RANDOMIZED | PARALLEL | 1PREVENTION | 4QUADRUPLE | false | 0ALL | false | The purpose of this study is to determine the effects of CLP on serum potassium and signs and symptoms of fluid overload in heart failure patients with chronic kidney disease. | null | Heart Failure | null | 2 | arm 1: Investigational drug: 15 g CLP per day given as capsules arm 2: Placebo, capsules | [
1,
2
] | 2 | [
0,
0
] | intervention 1: Oral administration intervention 2: Oral administration | intervention 1: CLP intervention 2: Placebo | 3 | Yerevan | N/A | Armenia | 44.5126 | 40.17765
Tbilisi | N/A | Georgia | 44.83412 | 41.69143
Chisinau | N/A | Moldova | 28.85938 | 47.00902 | 111 | 0 | 0 | 0 | NCT01265524 | 1COMPLETED | 2011-11-01 | 2011-04-01 | Sorbent Therapeutics | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 77 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | true | The purpose of this study is to assess the efficacy and safety of REGN727/SAR236553 in participants diagnosed with heterozygous familial hypercholesterolemia (heFH) | null | Hypercholesterolemia | null | 5 | arm 1: Placebo SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks. arm 2: Alirocumab 150 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks. arm 3: Alirocumab 200 mg SC injection Q4W added to stable statin regimen with or... | [
2,
0,
0,
0,
0
] | 2 | [
0,
0
] | intervention 1: Alirocumab two SC injections in the abdomen only. intervention 2: Placebo two SC injections in the abdomen only. | intervention 1: Alirocumab intervention 2: Placebo | 22 | Huntsville | Alabama | United States | -86.58594 | 34.7304
Mission Viejo | California | United States | -117.672 | 33.60002
Newport Beach | California | United States | -117.92895 | 33.61891
Bridgeport | Connecticut | United States | -73.18945 | 41.17923
Jacksonville | Florida | United States | -81.65565 | 30.33218
Mia... | 77 | 0 | 0 | 0 | NCT01266876 | 1COMPLETED | 2011-11-01 | 2011-01-01 | Regeneron Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | |
[
3
] | 256 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | The purpose of this study is to compare clinical response to the measurement techniques of several objective measures of clinical efficacy for use in future ABSSSI (Acute Bacterial Skin and Skin Structure Infection) clinical trials | null | Skin and Subcutaneous Tissue Bacterial Infections | null | 3 | arm 1: 300 mg IV (intravenous) every 12 hours for 5-14 days arm 2: 15 mg/kg, up to 1250 mg, IV every 12 hours for 5-14 dyas arm 3: 600 mg IV every 12 hours for 5-14 days | [
0,
1,
1
] | 3 | [
0,
0,
0
] | intervention 1: 300mg IV every 12 hours for 5-14 days intervention 2: 600mg IV every 12 hours for 5-14 days intervention 3: 15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days | intervention 1: Delafloxacin intervention 2: Linezolid intervention 3: Vancomycin | 31 | Mobile | Alabama | United States | -88.04305 | 30.69436
Montgomery | Alabama | United States | -86.29997 | 32.36681
Buena Park | California | United States | -117.99812 | 33.86751
Chula Vista | California | United States | -117.0842 | 32.64005
La Mesa | California | United States | -117.02308 | 32.76783
Los Angeles | C... | 249 | 0 | 0 | 0 | NCT01283581 | 1COMPLETED | 2011-11-01 | 2011-01-01 | Melinta Therapeutics, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | |
[
4
] | 243 | RANDOMIZED | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The primary purpose of this study is to test the feasibility of sending pre-cessation nicotine patches and to examine the effects associated with the pre-cessation treatment phase. Specifically, this study aims to:
1. See if subjects will use pre-cessation nicotine patches.
2. See if subjects in the pre-cessation nico... | Quitlines have become central to state tobacco control efforts in the U.S. In addition to offering telephone counseling, many quitlines have begun providing quitting aids (e.g., nicotine patch) to eligible smokers. The nicotine patch has been shown repeatedly to double the rate of quitting success compared to a placebo... | Smoking Cessation | tobacco cessation smoking cessation nicotine counseling telephone self-help smoking abstinence tobacco use disorder nicotine replacement therapy | null | 3 | arm 1: Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients will be encouraged to start using these patches PRIOR to their quit date.
Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4... | [
0,
1,
1
] | 2 | [
5,
0
] | intervention 1: Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, ano... | intervention 1: Telephone Counseling intervention 2: Nicotine Patches | 1 | San Diego | California | United States | -117.16472 | 32.71571 | 243 | 0 | 0 | 0 | NCT01287377 | 1COMPLETED | 2011-11-01 | 2010-11-01 | University of California, San Diego | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 85 | RANDOMIZED | CROSSOVER | 0TREATMENT | 4QUADRUPLE | false | 0ALL | null | This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149) on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). | null | COPD | COPD QVA149 tiotropium exercise exercise tolerance combination bronchodilator moderate to severe COPD | null | 3 | arm 1: QVA149 delivered once daily via single-dose dry powder inhaler. arm 2: Placebo, delivered once daily via single-dose dry powder inhaler. arm 3: Tiotropium delivered once daily via HandiHaler® device. | [
0,
2,
1
] | 3 | [
0,
0,
0
] | intervention 1: None intervention 2: None intervention 3: None | intervention 1: indacaterol and glycopyrronium bromide (QVA149) intervention 2: placebo intervention 3: tiotropium | 13 | Frankfurt | N/A | Germany | 10.53333 | 49.68333
Großhansdorf | N/A | Germany | 10.28333 | 53.66667
Hamburg | N/A | Germany | 9.99302 | 53.55073
Lübeck | N/A | Germany | 10.68729 | 53.86893
Mainz | N/A | Germany | 8.2791 | 49.98419
Rudersdorf | N/A | Germany | 11.45 | 51.1
Wiesbaden | N/A | Germany | 8.24932 | 50.08258
... | 237 | 0 | 0 | 0 | NCT01294787 | 1COMPLETED | 2011-11-01 | 2011-02-01 | Novartis Pharmaceuticals | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 439 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The primary purpose of the study is to evaluate the efficacy and safety of lubiprostone administration in subjects with Opioid-induced Bowel Dysfunction. | null | Opioid-induced Bowel Dysfunction | null | 2 | arm 1: 24 mcg capsules twice daily (BID) arm 2: 0 mcg capsules twice daily (BID) | [
0,
2
] | 2 | [
0,
0
] | intervention 1: 24 mcg administered orally twice daily (BID) intervention 2: Matching placebo, 0 mcg administered orally twice daily (BID) | intervention 1: Lubiprostone intervention 2: Placebo | 142 | Athens | Alabama | United States | -86.97219 | 34.80243
Birmingham | Alabama | United States | -86.80249 | 33.52066
Birmingham | Alabama | United States | -86.80249 | 33.52066
Birmingham | Alabama | United States | -86.80249 | 33.52066
Foley | Alabama | United States | -87.6836 | 30.40659
Montgomery | Alabama | United ... | 439 | 0 | 0 | 0 | NCT01298219 | 1COMPLETED | 2011-11-01 | 2010-12-01 | Sucampo Pharma Americas, LLC | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
4
] | 177 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery. | null | Inflammation Pain Cataract | null | 2 | arm 1: Mapracorat ophthalmic suspension arm 2: Vehicle of mapracorat ophthalmic suspension | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks. intervention 2: Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks. | intervention 1: Mapracorat intervention 2: Vehicle | 1 | Rochester | New York | United States | -77.61556 | 43.15478 | 177 | 0 | 0 | 0 | NCT01298752 | 6TERMINATED | 2011-11-01 | 2011-02-01 | Bausch & Lomb Incorporated | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
0
] | 66 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | true | The primary objective of this study is to compare the mean serum sodium after 48 hours of therapy with either 0.45% NaCl/dextrose 5% or 0.9% NaCl/dextrose 5%, in critically ill children requiring IV maintenance fluid administration. | In patients without possibilities of oral intake, maintenance fluids provide electrolytes and water. Since the original descriptions by Holliday and Segar, the recommended standard maintenance solutions are based on "physiological needs", containing 30-50 mEq/L of sodium.
However hyponatremia has become increasingly r... | Hyponatremia | hyponatremia maintenance solutions pediatrics | null | 2 | arm 1: Subjects in this arm will receive 0.45% NaCl/5% dextrose intravenous maintenance fluids. arm 2: Subjects in this arm will receive 0.9% NaCl/5% dextrose intravenous maintenance fluids. | [
1,
0
] | 2 | [
0,
0
] | intervention 1: 0.45% NaCl/5% dextrose IV maintenance fluids intervention 2: 0.9% NaCl/5% dextrose IV maintenance fluids | intervention 1: hypotonic intervention 2: isotonic | 1 | Buenos Aires | N/A | Argentina | -58.37723 | -34.61315 | 66 | 0 | 0 | 0 | NCT01301274 | 1COMPLETED | 2011-11-01 | 2011-02-01 | Hospital General de Niños Pedro de Elizalde | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 36 | RANDOMIZED | CROSSOVER | null | 3TRIPLE | false | 0ALL | false | This is an intra-subject crossover comparative safety study to evaluate the effect of intravenous (IV) bolus injection of SonoVue on pulmonary hemodynamics. | Subjects will be divided into two groups based on their baseline mean pulmonary arterial pressure. Each subject will receive two injections in randomized order during right heart catheterization: one administration of SonoVue and one administration of placebo, either SonoVue followed by Placebo or Placebo followed by S... | Pulmonary Hypertension | Pulmonary hypertension Right heart Catheterization | null | 2 | arm 1: Ultrasound contrast agent under development arm 2: normal saline 0.9% for injection used as the comparator | [
0,
2
] | 2 | [
0,
0
] | intervention 1: dose of 4.8 mL administered intravenously one time intervention 2: Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue) | intervention 1: SonoVue intervention 2: Placebo | 1 | Teaneck | New Jersey | United States | -74.01597 | 40.8976 | 36 | 0 | 0 | 0 | NCT01306292 | 1COMPLETED | 2011-11-01 | 2011-04-01 | Bracco Diagnostics, Inc | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2,
3
] | 12 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | true | 0ALL | true | Sports-related concussions are a serious problem in football, boxing, and other full contact sports. After experiencing consecutive concussions, there is an increase in neurological deficits that can lead to long-term cognitive problems (Dementia pugilistica). To combat this increase in brain damage, novel strategies n... | Each year, approximately 3 million sports-related concussions occur in athletes. Only about 5% of these concussions are treated in the hospital setting. To date, there are no effective interventions used at decreasing the levels of oxidant injury and inflammation within these athletes. The standard form of care in thes... | Sports Concussion | Mild Brain Injury Concussions Resveratrol Boxers ImPACT MRI | null | 2 | arm 1: Placebo control arm 2: Intervention | [
2,
0
] | 2 | [
0,
0
] | intervention 1: The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury. intervention 2: The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury. | intervention 1: Resveratrol intervention 2: Placebo | 1 | Dallas | Texas | United States | -96.80667 | 32.78306 | 12 | 0 | 0 | 0 | NCT01321151 | 1COMPLETED | 2011-11-01 | 2011-03-01 | University of Texas Southwestern Medical Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 29 | NON_RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of the trial was to determine the short-term effects of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) at various levels of renal function. | Renal function was assessed during screening with the estimated glomerular filtration rate (eGFR), which was calculated with the 4-variable modification of diet in renal disease (MDRD) equation using a minimum of 2 creatinine measurements. The eGFR values were used to categorize participants into 1 of 3 mutually exclus... | Autosomal Dominant Polycystic Kidney Disease | null | 3 | arm 1: Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM \[8 hours later\]) to the maximally tolerated dose. arm 2: Participants received tolvaptan for the first 3 weeks of... | [
0,
0,
0
] | 1 | [
0
] | intervention 1: Tolvaptan was supplied as 15 and 30 mg tablets. | intervention 1: Tolvaptan | 1 | Groningen | N/A | Netherlands | 6.56667 | 53.21917 | 29 | 0 | 0 | 0 | NCT01336972 | 1COMPLETED | 2011-11-01 | 2010-10-01 | Otsuka Pharmaceutical Development & Commercialization, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2
] | 26 | RANDOMIZED | CROSSOVER | 0TREATMENT | 2DOUBLE | false | 0ALL | false | This study will evaluate the safety and tolerability of MK-4618 when coadministered with antihypertensive agents and will evaluate changes in blood pressure following co-administration of MK-4618 with a beta blocker and a vasodilator. The primary hypothesis of the study is that MK-4618 does not result in a clinically m... | null | Hypertension | null | 4 | arm 1: Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows P... | [
0,
0,
0,
0
] | 4 | [
0,
0,
0,
0
] | intervention 1: Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7 intervention 2: Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7 intervention 3: Previously prescribed daily dose of open-label metoprolol for the duration of the study intervention 4... | intervention 1: MK-4618 intervention 2: Placebo for MK-4618 intervention 3: Metoprolol intervention 4: Amlodipine | 0 | null | 50 | 0 | 0 | 0 | NCT01337674 | 1COMPLETED | 2011-11-01 | 2011-04-01 | Merck Sharp & Dohme LLC | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 60 | RANDOMIZED | PARALLEL | 0TREATMENT | 0NONE | false | 0ALL | true | The purpose of this research study is to examine the effects of two commonly used anesthetic drugs, dexmedetomidine and propofol, have on the shape and muscle tone of the upper airway in children, adolescents, and young adults with a history of obstructive sleep apnea (OSA) having an MRI scan.
The results of this stud... | Patients with OSA are at risk for airway obstruction (a condition that makes it difficult to breath) during sedation and anesthesia. Dexmedetomidine and propofol are safe and effective drugs regularly used by anesthesiologists. These drugs are used to put patients to sleep for operations and certain studies like MRI sc... | Sleep Apnea, Obstructive | Obstructive Sleep Apnea MRI Pediatrics Dexmedetomidine Propofol Anesthesia | null | 2 | arm 1: None arm 2: None | [
1,
1
] | 2 | [
0,
0
] | intervention 1: Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump. intervention 2: Once an IV is in place, atropine 10 mcg/kg will be give... | intervention 1: Dexmedetomidine intervention 2: Propofol | 1 | Cincinnati | Ohio | United States | -84.51439 | 39.12711 | 60 | 0 | 0 | 0 | NCT01344759 | 1COMPLETED | 2011-11-01 | 2009-06-01 | Children's Hospital Medical Center, Cincinnati | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2
] | 4 | RANDOMIZED | FACTORIAL | 0TREATMENT | 0NONE | false | 0ALL | false | This pilot study will evaluate the implementation of a stepped care intervention that combines Cognitive-Behavioral Therapy, Motivational Interviewing, psychotropic medications, and information technology innovations at a level 1 trauma center to community linkage components to reduce the symptoms of posttraumatic stre... | The investigators plan to implement a pilot linkage program in which trauma center based care facilitators will use a population-based recruitment strategy to facilitate outpatient follow-up for acutely injured trauma center inpatients and emergency department patients. All patients recruited into the trial will be low... | Posttraumatic Stress Disorder | PTSD | null | 2 | arm 1: Combination of behavioral therapy and drug therapy arm 2: None | [
0,
1
] | 4 | [
5,
5,
0,
5
] | intervention 1: Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months. intervention 2: Motivational interviewing is designed to address alcohol and dr... | intervention 1: Cognitive Behavioral Therapy intervention 2: Motivational Interviewing intervention 3: FDA-Approved Anti-Anxiety Medications intervention 4: Standard Care Control | 1 | Seattle | Washington | United States | -122.33207 | 47.60621 | 4 | 0 | 0 | 0 | NCT01347541 | 6TERMINATED | 2011-11-01 | 2011-01-01 | University of Washington | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 237 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | This study is primarily a safety study. The primary and secondary endpoints are based on 24-hour Holter monitor assessments obtained on Day 14 relative to baseline. | null | Chronic Obstructive Pulmonary Disease | COPD | null | 4 | arm 1: PT005 MDI arm 2: PT001 MDI arm 3: PT003 MDI arm 4: Formoterol Fumarate 12 μg (Foradil® Aerolizer®) | [
0,
0,
0,
1
] | 4 | [
0,
0,
0,
0
] | intervention 1: PT005 MDI administered as two puffs BID for 14 days intervention 2: PT001 MDI administered as two puffs BID for 14 days intervention 3: PT003 MDI administered as two puffs BID for 14 days intervention 4: Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days | intervention 1: PT005 MDI intervention 2: PT001 MDI intervention 3: PT003 MDI intervention 4: Formoterol Fumarate 12 μg (Foradil® Aerolizer®) | 20 | Glendale | Arizona | United States | -112.18599 | 33.53865
Fullerton | California | United States | -117.92534 | 33.87029
Los Angeles | California | United States | -118.24368 | 34.05223
San Diego | California | United States | -117.16472 | 32.71571
Pensacola | Florida | United States | -87.21691 | 30.42131
Lafayette |... | 237 | 0 | 0 | 0 | NCT01349803 | 1COMPLETED | 2011-11-01 | 2011-05-01 | Pearl Therapeutics, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 185 | RANDOMIZED | CROSSOVER | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | The primary objective of this study is to demonstrate efficacy of PT003 MDI relative to its individual components (PT001 MDI and PT005 MDI) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). | null | Chronic Obstructive Pulmonary Disease | COPD | null | 6 | arm 1: PT003 MDI Dose 1 arm 2: PT003 MDI Dose 2 arm 3: PT003 MDI Dose 3 arm 4: PT003 MDI Dose 4 arm 5: PT001 MDI arm 6: PT005 MDI | [
0,
0,
0,
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: PT003 MDI administered as two puffs BID for 7 days intervention 2: PT001 MDI administered as two puffs BID for 7 days intervention 3: PT005 MDI administered as two puffs BID for 7 days | intervention 1: PT003 intervention 2: PT001 intervention 3: PT005 | 13 | Rancho Mirage | California | United States | -116.41279 | 33.73974
Colorado Springs | Colorado | United States | -104.82136 | 38.83388
Waterbury | Connecticut | United States | -73.0515 | 41.55815
Clearwater | Florida | United States | -82.8001 | 27.96585
Pensacola | Florida | United States | -87.21691 | 30.42131
Stock... | 350 | 0 | 0 | 0 | NCT01349816 | 1COMPLETED | 2011-11-01 | 2011-06-01 | Pearl Therapeutics, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 89 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 0ALL | false | This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, safety study of the effects of ciclesonide nasal aerosol (74 mcg) on the HPA axis when administered once daily to male and premenarchal female subjects 6 to 11 years of age with a diagnosis of PAR. | This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, safety study of the effects of ciclesonide nasal aerosol (74 mcg) on the HPA axis when administered once daily to male and premenarchal female subjects 6 to 11 years of age with a diagnosis of PAR.
The study requires that subjects be ... | Perennial Allergic Rhinitis PAR | Perennial Allergic Rhinitis PAR | null | 2 | arm 1: ciclesonide nasal aerosol (74 mcg) arm 2: None | [
0,
2
] | 2 | [
0,
0
] | intervention 1: ciclesonide nasal aerosol (74 mcg) intervention 2: Placebo | intervention 1: ciclesonide nasal aerosol intervention 2: Placebo | 7 | Costa Mesa | California | United States | -117.91867 | 33.64113
Stockbridge | Georgia | United States | -84.23381 | 33.54428
Normal | Illinois | United States | -88.99063 | 40.5142
Plymouth | Minnesota | United States | -93.45551 | 45.01052
El Paso | Texas | United States | -106.48693 | 31.75872
New Braunfels | Texas |... | 89 | 0 | 0 | 0 | NCT01378429 | 1COMPLETED | 2011-11-01 | 2011-07-01 | Sumitomo Pharma America, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 327 | RANDOMIZED | CROSSOVER | 0TREATMENT | 0NONE | false | 0ALL | false | This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus mometasone aqueous nasal spray. A novel patient-administered assessment, developed and validated to ... | This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus mometasone aqueous nasal spray. A novel patient-administered assessment, developed and validated to ... | Perennial Allergic Rhinitis | perennial allergic rhinitis PAR | null | 2 | arm 1: 74 mcg ciclesonide nasal aerosol once daily arm 2: 200 mcg mometasone aqueous nasal spray once daily | [
0,
1
] | 2 | [
0,
0
] | intervention 1: 74 mcg ciclesonide nasal aerosol once daily intervention 2: 200 mcg mometasone aqueous nasal spray once daily | intervention 1: ciclesonide intervention 2: mometasone | 15 | Huntington Beach | California | United States | -117.99923 | 33.6603
Mission Veijo | California | United States | N/A | N/A
San Diego | California | United States | -117.16472 | 32.71571
San Diego | California | United States | -117.16472 | 32.71571
Colorado Springs | Colorado | United States | -104.82136 | 38.83388
No... | 623 | 0 | 0 | 0 | NCT01401465 | 1COMPLETED | 2011-11-01 | 2011-07-01 | Sumitomo Pharma America, Inc. | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2,
3
] | 12 | NON_RANDOMIZED | CROSSOVER | null | 2DOUBLE | true | 0ALL | true | The investigators propose to study oral commercial silver nanoparticle products on human enzyme activity. | null | Healthy | null | 2 | arm 1: 14 Days Active Silver Solution arm 2: No Silver Nanoparticles | [
0,
2
] | 2 | [
0,
0
] | intervention 1: Oral silver dose of 32ppm intervention 2: Sterile Water No Silver | intervention 1: 32ppm Silver Particle intervention 2: Placebo | 1 | Salt Lake City | Utah | United States | -111.89105 | 40.76078 | 24 | 0 | 0 | 0 | NCT01405794 | 1COMPLETED | 2011-11-01 | 2011-07-01 | University of Utah | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 80 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | true | Primary purpose of this study is to determine if pregnenolone supplementation is associated with greater improvement in depressive symptoms of patients with bipolar disorder. Also the study will explore possibilities of improving anxiety and manic symptoms as well as the patient's cognition. | Determine if pregnenolone supplementation is associated with greater improvement in depressive symptoms than placebo in persons with Bipolar Depression (BPD), depressed phase. In our pilot study, pregnenolone showed a strong signal on depression scores.
Secondary
1. Determine if pregnenolone supplementation is associ... | Bipolar Disorder Major Depressive Disorder | null | 2 | arm 1: This arm will be given 50mg Pregnenolone twice per day for 2 weeks, then 150mg Pregnenolone twice per day for 2 weeks, then 250mg Pregnenolone twice per day for 8 weeks. arm 2: The arm will be given placebo that matches the Pregnenolone at the same frequency as the Pregnenolone for 12 weeks. | [
1,
2
] | 2 | [
0,
0
] | intervention 1: Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system. intervention 2: Inactive ingredient matching the active medication in appearance. | intervention 1: Pregnenolone intervention 2: Placebo | 1 | Dallas | Texas | United States | -96.80667 | 32.78306 | 73 | 0 | 0 | 0 | NCT01409096 | 1COMPLETED | 2011-11-01 | 2010-03-01 | University of Texas Southwestern Medical Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 10 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine. | PRÉCIS Protocol Title Creatine Safety \& Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety \& Tolerability Extension Study of Creatine in Subjects with HD
Study Phase Phase II Clinical Trial
Funding Departmental Funds
Drug Supply Provided By The Avicena Group, Inc (Palo Al... | Huntington's Disease (HD) | Symptomatic Huntington's Disease HD | null | 1 | arm 1: single arm long-term open label follow-up | [
5
] | 1 | [
0
] | intervention 1: Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose | intervention 1: Creatine monohydrate | 1 | Charlestown | Massachusetts | United States | -71.062 | 42.37787 | 10 | 0 | 0 | 0 | NCT01412151 | 1COMPLETED | 2011-11-01 | 2005-04-01 | Massachusetts General Hospital | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
0
] | 314 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | true | Tonsillectomy (removal of the tonsils) is a very common surgery in children. Bleeding after tonsillectomy is one of the risks of this surgery and can be more dangerous in children since they have less blood volume than adults. In order to improve recovery after tonsillectomy, steroids (medication that is a strong anti-... | Detailed description is entered above | Post-operative Hemorrhage | null | 2 | arm 1: Placebo is described in chart arm 2: Dexamethasone is described in chart | [
2,
0
] | 1 | [
0
] | intervention 1: 0.5mg/kg (max dose 20mg) | intervention 1: Dexamethasone | 1 | Boston | Massachusetts | United States | -71.05977 | 42.35843 | 314 | 0 | 0 | 0 | NCT01415583 | 1COMPLETED | 2011-11-01 | 2010-07-01 | Massachusetts Eye and Ear Infirmary | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | |
[
3
] | 103 | RANDOMIZED | PARALLEL | 0TREATMENT | 3TRIPLE | false | 0ALL | false | The purpose of this study was to describe the ocular discomfort immediately upon instillation of Brinzolamide 1%/Brimonidine 0.2% Tartrate Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension, and Brimonidine Tartrate 0.2% Ophthalmic Solution in subjects with open-angle glaucoma and/or ocular hypertension. | null | Open-Angle Glaucoma Ocular Hypertension | Open-Angle Glaucoma Ocular Hypertension Intraocular Pressure Brinzolamide Brimonidine | null | 3 | arm 1: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each affected eye 3 times a day for 7 days arm 2: Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each affected eye 3 times a day for 7 days arm 3: Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in ... | [
0,
1,
1
] | 3 | [
0,
0,
0
] | intervention 1: None intervention 2: None intervention 3: None | intervention 1: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension intervention 2: Brinzolamide ophthalmic suspension, 1% intervention 3: Brimonidine tartrate ophthalmic solution, 0.2% | 0 | null | 101 | 0 | 0 | 0 | NCT01426867 | 1COMPLETED | 2011-11-01 | 2011-09-01 | Alcon Research | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
2
] | 24 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | true | 0ALL | false | The purpose of this study is to study how the body processes digoxin and the effect of dulaglutide on how digoxin is processed by the body. Information about any side effects that may occur will also be collected.
This study is for research purposes only and is not intended to treat any medical condition. This researc... | null | Diabetes Mellitus, Type 2 | null | 1 | arm 1: Digoxin: Two 0.5-milligram (mg) doses, oral, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, oral, once daily on Day 2 to Day 17.
Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15. | [
0
] | 2 | [
0,
2
] | intervention 1: Administered orally intervention 2: Administered as subcutaneous injection | intervention 1: Digoxin intervention 2: Dulaglutide | 1 | Daytona Beach | Florida | United States | -81.02283 | 29.21081 | 45 | 0 | 0 | 0 | NCT01436201 | 1COMPLETED | 2011-11-01 | 2011-09-01 | Eli Lilly and Company | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2
] | 18 | RANDOMIZED | CROSSOVER | 0TREATMENT | 0NONE | true | 0ALL | null | Investigation of food effect on the bioavailability of a 25 mg empagliflozin tablet and assessment of dose proportionality between 10 mg and 25 mg empagliflozin tablets under fasting conditions. | null | Healthy | null | 3 | arm 1: high dose of empagliflozin after overnight fasting for at least 10 h arm 2: high dose of empagliflozin after a standardised high fat breakfast arm 3: low dose empagliflozin after overnight fasting for at least 10 h | [
0,
0,
0
] | 3 | [
0,
0,
0
] | intervention 1: high dose of empagliflozin after overnight fasting for at least 10 h intervention 2: low dose empagliflozin after overnight fasting for at least 10 h intervention 3: high dose of empagliflozin after a standardised high fat breakfast | intervention 1: Empagliflozin intervention 2: Empagliflozin intervention 3: Empagliflozin | 1 | Biberach | N/A | Germany | 8.03333 | 48.33333 | 54 | 0 | 0 | 0 | NCT01451775 | 1COMPLETED | 2011-11-01 | 2011-10-01 | Boehringer Ingelheim | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
5
] | 255 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | false | The purpose of this study is to determine the onset of action of two commercially available over-the-counter antihistamines (Loratadine and
Fexofenadine) in a model of seasonal allergic rhinitis (SAR). Participants undergo sensitization exposures to Mountain Cedar (juniperus ashei) pollen in a Biogenics Research Chamb... | null | Rhinitis | null | 3 | arm 1: Participants will receive one dose of loratadine following randomization at 120 minutes of exposure during visit 4. arm 2: Participants will receive one dose of fexofenadine following randomization at 120 minutes of exposure during visit 4. arm 3: Participants will receive one dose of placebo following randomiza... | [
0,
0,
2
] | 4 | [
0,
0,
0,
0
] | intervention 1: loratadine, one 10 mg tablet, orally intervention 2: fexofenadine, one 180 mg tablet, orally intervention 3: one tablet, orally intervention 4: one tablet, orally | intervention 1: loratadine intervention 2: fexofenadine intervention 3: placebo to loratadine intervention 4: placebo to fexofenadine | 0 | null | 255 | 0 | 0 | 0 | NCT01469234 | 1COMPLETED | 2011-11-01 | 2011-10-01 | Bayer | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2
] | 6 | NA | SINGLE_GROUP | 9OTHER | 0NONE | true | 2MALE | null | This single center, open-label, non-randomized, one-treatment, one-period study will evaluate the metabolic profile and the safety of a single oral radiolabeled dose of dalcetrapib in male healthy volunteers. | null | Healthy Volunteer | null | 1 | arm 1: None | [
0
] | 1 | [
0
] | intervention 1: Single oral radiolabeled dose | intervention 1: dalcetrapib | 1 | Zuidlaren | N/A | Netherlands | 6.68194 | 53.09417 | 6 | 0 | 0 | 0 | NCT01476267 | 1COMPLETED | 2011-11-01 | 2011-10-01 | Hoffmann-La Roche | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
2,
3
] | 40 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 0ALL | false | The goal of this clinical research study is to see if high-dose chemotherapy (BEAM) and rituximab, given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells is safe. Another goal is to learn if this treatment can help decrease the chances of the cancer coming back. | BEAM chemotherapy is the standard treatment for lymphoma. BEAM is a combination of chemotherapy drugs (carmustine, cytarabine, etoposide, and melphalan). Rituximab is an antibody made from human and mouse proteins. It reacts with a certain molecule on the surface of lymphoma cells and helps the body's immune system des... | Lymphoma | Lymphoma Relapse B-cell CD20+ non-Hodgkin's lymphoma High-dose BEAM chemotherapy Y Zevalin In Zevalin Rituxan Rituximab BCNU 1,3-bis(2-chloroethyl)-1-nitrosourea bis-chloronitrosourea Carmustine BiCNU VP-16 Ara-C Cytarabine Cytosar DepoCyt Cytosine Arabinosine Hydrochloride Melphalan Alkeran G-CSF Filgrastim Neupogen S... | null | 1 | arm 1: Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (20... | [
0
] | 9 | [
0,
0,
0,
0,
0,
0,
0,
3,
0
] | intervention 1: Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14. intervention 2: Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21. intervention 3: 250 mg/m2 by vein on Day -21 and on Day -14.
1000 mg/m2 by vein on Days +1 and +8. intervention 4: 300 mg/m2 by vein on Day -6. interve... | intervention 1: Y Zevalin intervention 2: In Zevalin intervention 3: Rituxan intervention 4: BCNU intervention 5: VP -16 intervention 6: Ara-C intervention 7: Melphalan intervention 8: Stem Cell Infusion intervention 9: G-CSF | 1 | Houston | Texas | United States | -95.36327 | 29.76328 | 40 | 0 | 0 | 0 | NCT01538472 | 1COMPLETED | 2011-11-01 | 2003-09-01 | M.D. Anderson Cancer Center | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
4
] | 31 | RANDOMIZED | PARALLEL | 0TREATMENT | 4QUADRUPLE | false | 2MALE | false | The purpose of this study is to develop new treatment options for osteoporosis in men. The Investigators will study two medications and three treatment regimens. First, risedronate (FDA approved) will be studied as monotherapy. Second, the investigators will study injectable parathyroid hormone (PTH 134, teriparatide; ... | Study Design:
This study involves a 24month commitment, constituting 12 visits as outlined below. The study coordinator will contact patients remotely by phone or email at the Month 9 visit, the Month 15, and the Month 21 visit so these do not require travel to Columbia University Medical Center.
This randomized, dou... | Osteoporosis | osteoporosis male | null | 3 | arm 1: Active Risedronate + Placebo Teriparatide for 18 months / Active Risedronate for 6 months arm 2: Active Risedronate + Active Teriparatide for 18 months / Active Risedronate for 6 months arm 3: Placebo Risedronate Active Teriparatide for 18 months / Active Risedronate for 6 months | [
1,
1,
1
] | 4 | [
0,
0,
0,
0
] | intervention 1: weekly risedronate intervention 2: daily teriparatide intervention 3: daily placebo of teriparatide intervention 4: weekly placebo of Risedronic Acid | intervention 1: Risedronate intervention 2: Teriparatide intervention 3: Placebo Teriparatide intervention 4: placebo Risedronate | 1 | New York | New York | United States | -74.00597 | 40.71427 | 29 | 0 | 0 | 0 | NCT01611571 | 1COMPLETED | 2011-11-01 | 2003-12-01 | Columbia University | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
5
] | 19 | RANDOMIZED | PARALLEL | 9OTHER | 2DOUBLE | true | 1FEMALE | false | The purpose of this study is to assess the fields of anhydrotic effect (FAE) of abobotulinumtoxinA and onabotulinumtoxinA at the same labeled unit dose (1:1 units), comparing both sweat gland and muscle activity. | This is a prospective, single-center, randomized, double-blind study. All participants were recruited from a research center in Porto Alegre, Brazil, and provided written informed consent. The purpose of this study is to assess the fields of anhydrotic effect (FAE) of abobotulinumtoxinA and onabotulinumtoxinA at the sa... | Skin Wrinkling | wrinkles botulinum toxin abobotulinumtoxinA onabotulinumtoxinA field of anhydrotic effects | null | 2 | arm 1: Patients were randomized to the side of the forehead (left or right) in which the products were administered. All the patients received abobotulinumtoxin A in one of the sides of the forehead. arm 2: Patients were randomized to the side of the forehead (left or right) in which the products were administered. All... | [
1,
1
] | 2 | [
0,
0
] | intervention 1: Isovolumetric (0.02 mL) doses of 2 units of abobotulinumtoxinA injected on one side of the forehead. intervention 2: Isovolumetric (0.02 mL) doses of 2 units of onabotulinumtoxinA injected on the other side of the forehead. | intervention 1: AbobotulinumtoxinA (ABO) intervention 2: OnabotulinumtoxinA (ONA) | 1 | Porto Alegre | Rio Grande do Sul | Brazil | -51.23019 | -30.03283 | 38 | 0 | 0 | 0 | NCT01732809 | 1COMPLETED | 2011-11-01 | 2011-01-01 | Brazilan Center for Studies in Dermatology | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
[
3
] | 5 | NA | SINGLE_GROUP | 0TREATMENT | 0NONE | false | 1FEMALE | true | The protocol will study the effect of the combination of two drugs-Abraxane and Bevacizumab-on a subject's ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. This study drug combination will be given to subjects who have already been treated for their cancer with other chemotherapy, and now their canc... | null | Ovarian Cancer Peritoneal Cancer | null | 1 | arm 1: Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion. | [
0
] | 2 | [
0,
0
] | intervention 1: Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion. intervention 2: Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abrax... | intervention 1: Abraxane intervention 2: Bevacizumab | 1 | Portland | Oregon | United States | -122.67621 | 45.52345 | 5 | 0 | 0 | 0 | NCT01821859 | 6TERMINATED | 2011-11-01 | 2010-01-01 | OHSU Knight Cancer Institute | 7OTHER | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
[
3
] | 154 | RANDOMIZED | PARALLEL | 0TREATMENT | 2DOUBLE | false | 0ALL | null | This study will evaluate the efficacy and safety of sequential administration of Tarceva and gemcitabine/platinum chemotherapy in patients with stage IIIb/IV non-small cell lung cancer. Patients will be randomized to receive Tarceva (150 mg po) or placebo on days 15-28 of a 4 week cycle of intravenous platinum-based ch... | null | Non-Small Cell Lung Cancer | null | 2 | arm 1: None arm 2: None | [
0,
2
] | 5 | [
0,
0,
0,
0,
0
] | intervention 1: 150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily intervention 2: orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application intervention 3: 1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles intervention 4: ... | intervention 1: erlotinib [Tarceva] intervention 2: placebo intervention 3: gemcitabine intervention 4: cisplatin intervention 5: carboplatin | 19 | Campbelltown | N/A | Australia | 150.81667 | -34.06667
Camperdown | N/A | Australia | 151.17642 | -33.88965
Liverpool | N/A | Australia | 150.92588 | -33.91938
Guangzhou | N/A | China | 113.25 | 23.11667
Guangzhou | N/A | China | 113.25 | 23.11667
Shanghai | N/A | China | 121.45806 | 31.22222
Shanghai | N/A | China | 1... | 153 | 0 | 0 | 0 | NCT01998919 | 1COMPLETED | 2011-11-01 | 2006-08-01 | Hoffmann-La Roche | 4INDUSTRY | false | false | false | null | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.